Method for producing RNA

By cultivating ribonuclease III-deficient coryneform bacteria to express and accumulate RNA, the method achieves efficient and high-yield RNA production, overcoming inefficiencies in existing RNA production methods.

JP2024163248AInactive Publication Date: 2024-11-21AJINOMOTO CO INC
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2024152139
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2017-08-24
Filing Date
2024-09-04
Publication Date
2024-11-21
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing methods for producing RNA using microorganisms are inefficient and do not effectively utilize ribonuclease III-deficient hosts to enhance RNA production.

Method used

The method involves cultivating coryneform bacteria with reduced ribonuclease III activity, expressing target RNA within the bacterial body, and accumulating it for collection, using modified strains with ribonuclease III activity reduced by genetic modifications or protein inactivation.

Benefits of technology

This approach significantly enhances RNA production capacity, allowing for higher yields of target RNA, up to several milligrams per liter of culture, by minimizing RNA degradation within the bacterial host.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024163248000004
    Figure 2024163248000004
  • Figure 2024163248000005
    Figure 2024163248000005
  • Figure 2024163248000006
    Figure 2024163248000006
Patent Text Reader

Abstract

To provide a method for producing RNA.SOLUTION: The objective RNA is produced by culturing a coryneform bacterium having an expression unit for the objective RNA, which has been modified so that the activity of ribonuclease III is reduced, in a medium, to express the objective RNA and accumulate the objective RNA in the cells of the bacterium, and collecting the objective RNA from the cells.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for producing RNA (ribonucleic acid) by fermentation using microorganisms. [Background technology]

[0002] As an example of a method for producing RNA using microorganisms, RNA is accumulated in Escherichia coli cells that are deficient in ribonuclease III (RNase III). (Non-Patent Document 1), and a method in which RNA is accumulated in the capsid using Pseudomonas syringae as a host by utilizing the function of φ6 bacteriophage ( Non-patent literature 2) used Escherichia coli as a host, and transformed the RNA with a partial sequence of tRNA into the bacterial cells. In another method, Escherichia coli is used as a host and siRNA is bound to it (Non-Patent Document 3). a method for producing the RNA by forming a complex with a protein that binds to the RNA (Non-Patent Document 4), a method for producing the RNA by secreting it using a bacterium of the genus Rhodovulum as a host (Patent Document 1), and a method for producing the RNA by secreting it using a yeast as a host. As a countermeasure, a method for accumulating RNA in yeast mitochondria (Patent Document 2) is known. [Prior art documents] [Patent documents]

[0003] [Patent Document 1] WO2009 / 063969 [Patent Document 2] WO2010 / 084371 [Non-patent literature]

[0004] [Non-Patent Document 1] Tenllado F, et. al., Crude extracts of bacterially expressed dsRNA can be used to protect plants against virus infections. BMC Biotechnol. 2003 Mar 20;3:3. [Non-Patent Document 2] Aalto AP, et. al., Large-scale production of dsRNA and siRNA pools for RNA interference utilizing bacteriophage phi6 RNA-dependent RNA polymerase. RNA. 2007 Mar;13(3):422-9. [Non-Patent Document 3] Ponchon L, et. al., A generic protocol for the expression and purification of recombinant RNA in Escherichia coli using a tRNA scaffold. Nat Protoc. 2009;4(6):947-59. [Non-Patent Document 4] Huang L, et. al., Efficient and specific gene knockdown by small interfering RNAs produced in bacteria. Nat Biotechnol. 2013 Apr;31(4):350-6. Summary of the Invention [Problem to be solved by the invention]

[0005] An objective of the present invention is to provide an efficient method for producing RNA. [Means for solving the problem]

[0006] The present inventors have found that RNA can be efficiently produced by expressing RNA in a coryneform bacterium lacking ribonuclease III (RNase III), and have completed the present invention.

[0007] That is, the present invention can be exemplified as follows. [1] A method for producing a target RNA, comprising the steps of: Cultivating a coryneform bacterium having an expression unit for a target RNA in a medium, expressing the target RNA, and accumulating the target RNA in the cells of the bacterium; and collecting target RNA from the bacterial cells; Including, The bacterium is modified so that RNase III activity is reduced compared to a non-modified strain. The way it is done. [2] The ribonuclease III is a protein selected from the group consisting of (a), (b), and (c) below: The method, (a) a protein comprising the amino acid sequence set forth in SEQ ID NO:52; (b) an amino acid sequence including a substitution, deletion, insertion, and / or addition of 1 to 10 amino acid residues in the amino acid sequence shown in SEQ ID NO: 52, and which inhibits ribonuclease III Proteins with activity; (c) a protein comprising an amino acid sequence having 90% or more identity to the amino acid sequence shown in SEQ ID NO:52 and having ribonuclease III activity. [3] By reducing the expression of the gene encoding RNase III or by inhibiting the expression of the gene The method as described above, wherein the activity of ribonuclease III is reduced by disrupting the gene. [4] The method as described above, wherein the activity of ribonuclease III is reduced by deleting a gene encoding ribonuclease III. [5] The method as described above, wherein the bacterium has the expression unit at a copy number of 5 copies / cell or more. [6] The method as described above, wherein the bacterium has the expression unit at a copy number of 70 copies / cell or more. [7] The method, wherein the bacterium comprises a vector comprising the expression unit. [8] The above method, wherein the expression unit comprises, in the 5' to 3' direction, a promoter sequence that functions in a coryneform bacterium and a nucleotide sequence that encodes a target RNA. [9] The method, wherein the promoter sequence is a phage-derived promoter.

[10] The method, wherein the promoter sequence is an F1 promoter or a T7 promoter.

[11] The method, wherein the promoter sequence is a promoter described in the following (a) or (b): (a) a promoter comprising the nucleotide sequence shown in SEQ ID NO: 13 or 78; (b) a promoter comprising a nucleotide sequence having 90% or more identity to the nucleotide sequence shown in SEQ ID NO: 13 or 78.

[12] The method as described above, wherein the bacterium is a Corynebacterium bacterium.

[13] The method, wherein the bacterium is Corynebacterium glutamicum. [Brief description of the drawings]

[0008] [Figure 1] FIG. 1 is a diagram showing the construction procedure of plasmid pPBS4SΔrnc. [Diagram 2] Agarose gel electrophoresis diagram (photo) to confirm rnc gene deletion. [Diagram 3] A diagram showing the construction procedure of plasmid pVC7-sacB. [Figure 4] A diagram showing the construction procedure of plasmid pVC7-Pf1-U1Ainsert. [Diagram 5] Diagram showing the construction procedure of the plasmids. (A) pVC7-Pf1-Hv-iap. (B) pVC7-Pf1-Hv-iap-Pf1rev. [Figure 6] Agarose gel electrophoresis diagram (photo) showing the effect of deleting the rnc gene on improving RNA production. [Figure 7] Agarose gel electrophoresis diagram (photo) showing the effect of increasing the copy number of an RNA expression plasmid on improving RNA production. [Figure 8] A diagram showing the construction procedure of plasmid pL4440-Pt7-U1Ainsert. [Figure 9] A diagram showing the construction procedure of plasmid pL4440-Pt7-Hv-iap-Pt7rev. [Figure 10] Agarose gel electrophoresis diagram (photo) showing the comparison of RNA production by the F1 promoter expression system in C. glutamicum and the T7 promoter inducible expression system in E. coli. [Figure 11] A diagram showing the construction procedure of plasmid pPK4 XB-T7 ter. [Figure 12] A diagram showing the construction procedure of plasmid pPK-T7lac. [Figure 13] A diagram showing the construction procedure of plasmid pPK-T7lac-vd-antiOlac. [Figure 14] A diagram showing the construction procedure of plasmid pVC54. [Figure 15] A diagram showing the construction procedure of plasmid pBS5t-ptrB*. [Figure 16] A diagram showing the construction procedure of plasmid pBS5t-ptrB*-2Ter. [Figure 17] A diagram showing the construction procedure of plasmid pBS5t-ptrB*-T7pol. [Figure 18] A diagram showing the construction procedure of plasmid pVC54-T7pol. [Figure 19]Agarose gel electrophoresis showing RNA production by the T7 promoter-inducible expression system in C. glutamicum (photo). Lanes 1-2 and 6-7: Clone A, Lanes 3-4 and 8-9: Clone B, Lane 5: Century-Plus RNA Marker (Ambion AM7145). [Figure 20] A diagram showing the construction procedure of plasmid pPK4-T7pol. [Figure 21] A diagram showing the construction procedure of plasmid pVC7-Pt7-Hv-iap-Pt7rev. [Figure 22] Agarose gel electrophoresis diagram showing RNA production by the T7 promoter-inducible expression system in C. glutamicum (photo). [Figure 23] Agarose gel electrophoresis diagram (photo) showing RNA production by the high-copy-number plasmid pPK4H1. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] The present invention will be described in detail below.

[0010] The method of the present invention comprises culturing a coryneform bacterium having an expression unit for a target RNA in a medium. and harvesting the transcribed RNA of interest, wherein the bacterium has been modified to reduce RNase III activity. The coryneform bacterium used in the above is also referred to as the "bacterium of the present invention."

[0011] <1> The bacteria of the present invention The bacterium of the present invention is a coryneform bacterium having an expression unit for a target RNA which has been modified so as to reduce ribonuclease III activity.

[0012] The bacterium of the present invention can be obtained by introducing an expression unit for a target RNA into a coryneform bacterium and reducing ribonuclease III activity. In the present invention, modifications for constructing the bacterium of the present invention can be performed in any order. That is, the bacterium of the present invention can be obtained, for example, by introducing an expression unit for a target RNA into a coryneform bacterium and then modifying the coryneform bacterium so that ribonuclease III activity is reduced. The bacterium of the present invention can also be obtained, for example, by modifying a coryneform bacterium so that ribonuclease III activity is reduced. Alternatively, the target RNA can be expressed by introducing the expression unit into a coryneform bacterium after the synthesis of the target RNA. The bacterium of the present invention or the bacterium from which it is constructed is also referred to as a "host".

[0013] The bacterium of the present invention has the ability to produce a target RNA (the ability to produce a target RNA). Specifically, the bacterium of the present invention has the ability to produce a target RNA by having at least an expression unit for the target RNA. The bacterium may have acquired the ability to produce the target RNA by a combination of introduction of an expression unit for the target RNA and reduction of ribonuclease III activity. The strain before being modified to reduce the RNase III activity may or may not be capable of producing the target RNA, assuming that the strain has an expression unit for the target RNA. It's okay.

[0014] The bacterium of the present invention may have any properties as long as it has the ability to produce the target RNA. The bacteria of interest do not contain any vectors, such as plasmids, other than the vector containing the expression unit of the target RNA. That is, for example, when the bacterium of the present invention inherently has a plasmid, the plasmid may be cured (removed).

[0015] <1-1> Corynebacterium capable of producing the target RNA In the present invention, a "bacterium capable of producing a target RNA" refers to a bacterium capable of producing a target RNA when cultured in a medium. A bacterium capable of expressing a target RNA and accumulating it in its cells to such an extent that it can be recovered. Bacteria capable of producing a target RNA can accumulate a larger amount of the target RNA in its cells than non-modified strains. The term "non-modified strain" refers to a bacterium that has been modified so as to reduce RNase III activity. The term refers to an unmodified control strain. In other words, examples of unmodified strains include wild-type strains and parent strains. In addition, bacteria capable of producing the target RNA are, for example, 1 mg / L or more of culture medium, 2 mg / L or more of culture medium, and 1 mg / L or more of culture medium. liquid or more, 5 mg / L-culture liquid or more, 10 mg / L-culture liquid or more, 20 mg / L-culture liquid or more, 50 mg / L-culture The bacterium may be capable of accumulating the RNA of interest intracellularly in an amount of 100 mg / L or more of culture medium.

[0016] In the present invention, a coryneform bacterium is used as a host. Examples of the coryneform bacterium include the genus Corynebacterium, the genus Brevibacterium, Mycobacterium, and the like. Mycobacterium and Microbacterium Examples of bacteria that belong to the genera include:

[0017] Specific examples of coryneform bacteria include the following species: Corynebacterium acetoacidophilum Corynebacterium acetoglutamicum Corynebacterium alkanolyticum Corynebacterium callunae Corynebacterium crenatum Corynebacterium glutamicum Corynebacterium lilium Corynebacterium melassecola Corynebacterium thermoaminogenes (Corynebacterium efficiens) Corynebacterium herculis Brevibacterium divaricatum (Corynebacterium glutamicum) Brevibacterium flavum (Corynebacterium glutamicum) flavum (Corynebacterium glutamicum)) Brevibacterium immariophilum Brevibacterium lactofermentum (Corynebacterium glutamicum) Brevibacterium roseum Brevibacterium saccharolyticum Brevibacterium thiogenitalis Corynebacterium ammoniagenes (Corynebacterium stationis) Brevibacterium album Brevibacterium cerinum Microbacterium ammoniaphilum

[0018] Specific examples of coryneform bacteria include the following strains: Corynebacterium acetoacidophilum ATCC 13870 Corynebacterium acetoglutamicum ATCC 15806 Corynebacterium alkanolyticum ATCC 21511 Corynebacterium callunae ATCC 15991 Corynebacterium crenatum AS1.542 Corynebacterium glutamicum ATCC 13020, ATCC 13032, ATCC 13060, ATCC 13869, FERM BP-734 Corynebacterium lilium ATCC 15990 Corynebacterium melassecola ATCC 17965 Corynebacterium efficiens (Corynebacterium thermoaminogenes) AJ12340 (FERM BP-1539) Corynebacterium herculis ATCC 13868 Brevibacterium divaricatum (Corynebacterium glutamicum) ATCC 14020 Brevibacterium flavum (Corynebacterium glutamicum) ATCC 13826, ATCC 14067, AJ12418 (FERM BP-2205) Brevibacterium immariophilum ATCC 14068 Brevibacterium lactofermentum (Corynebacterium glutamicum) ATCC 13869 Brevibacterium roseum ATCC 13825 Brevibacterium saccharolyticum ATCC 14066 Brevibacterium thiogenitalis ATCC 19240 Corynebacterium ammoniagenes (Corynebacterium stationis) ATCC 6871, ATCC 6872 Brevibacterium album ATCC 15111 Brevibacterium cerinum ATCC 15112 Microbacterium ammoniaphilum ATCC 15354

[0019] The genus Corynebacterium includes bacteria that were previously classified as Brevibacterium but have now been integrated into the genus Corynebacterium (Int. J. Syst. Bacteriol., 41, 255(1991)). This includes bacteria that were previously classified as Corynebacterium ammoniagenes but were reclassified as Corynebacterium stathionis based on 16S rRNA sequence analysis and other factors (Int. J. Syst. Evol. Microbiol., 60, 874-879(2010)).

[0020] These strains can be obtained, for example, from the American Type Culture Collection (Address: 12301 Parklawn Drive, Rockville, Maryland 20852 PO Box 1549, Manassas, VA 20108, United States of America). Each strain has been assigned a registration number, which can be used to obtain the strain (see http: / / www.atcc.org / ). The registration numbers for each strain are listed in the catalogue of the American Type Culture Collection, and these strains can be obtained, for example, from the depository institution where the strain was deposited.

[0021] <1-2> Introduction of target RNA expression unit The bacterium of the present invention has an expression unit for a target RNA. Lineagenform bacteria can be obtained by introducing an expression unit of a target RNA into a coryneform bacterium. .

[0022] "Target RNA" refers to an RNA produced by the method of the present invention. In the present invention, one type of target RNA may be produced, or two or more types of target RNA may be produced.

[0023] The target RNA is not particularly limited as long as it is an RNA foreign to the host, i.e., an RNA other than the host's RNA. The target RNA can be appropriately selected depending on various conditions such as the intended use of the target RNA. The target RNA may be, for example, a naturally occurring RNA, or a modified RNA thereof. The target RNA may be, for example, RNA derived from a microorganism, RNA derived from a plant, or RNA derived from an animal. The target RNA may be, for example, mRNA (messenger RNA). It may be a coding RNA, or a non-coding RNA such as rRNA (ribosomal RNA), tRNA (transfer RNA), miRNA (micro RNA), siRNA (small interfering RNA), ribozyme, or RNA aptamer. Examples of mRNA include enzymes, receptors, transporters, antibodies, The target RNA may code for a protein having some function, such as a structural component or a regulatory factor, or may code for a protein that does not have any function itself. The term "protein" as used herein also includes so-called peptides, such as oligopeptides and polypeptides. The target RNA is, for example, an RNA having the base sequence of the above-mentioned RNA. The target RNA may be, for example, an RNA having a partial sequence of the base sequence of the RNA described above. The target RNA may be, for example, an RNA having the base sequence of the above-mentioned RNA or a complementary sequence of a partial sequence thereof. The target RNA may be, for example, an RNA having a variant sequence of the base sequence of the above-mentioned RNA, a partial sequence thereof, or a complementary sequence thereof. The variant sequence may be a variant sequence of the ribonuclease III gene described later. The description of the variants can be applied mutatis mutandis. The target RNA may have a combination of two or more base sequences selected from the base sequences of the above-mentioned RNAs, partial sequences thereof, complementary sequences thereof, and variant sequences thereof. Specifically, these include the partial sequence of the mRNA for the apoptosis inhibitor of the 20-spotted ladybird (Henosepilachna vigintioctopunctata) and the partial sequence of the mRNA for subunits A and E that make up the vacuolar ATPase of the Colorado potato beetle (Leptinotarsa ​​decemlineata).

[0024] The target RNA may be, for example, a single-stranded RNA (RNA consisting of one RNA strand) or a double-stranded RNA (RNA consisting of two RNA strands). Double-stranded RNA is a single type of RNA molecule. It may be a double-stranded molecule (homoduplex) consisting of two different RNA molecules. The double-stranded RNA may be, for example, a double-stranded RNA consisting of a certain RNA strand and its complementary strand. The target RNA may be, for example, a single RNA strand and The target RNA may be double-stranded, consisting of one DNA strand. The target RNA may contain both single-stranded and double-stranded regions. That is, for example, a single-stranded RNA may be partially double-stranded within the molecule. For example, the double-stranded RNA may form a structure (e.g., a stem-loop structure). , and may partially contain a single-stranded structure.

[0025] The length of the target RNA is not particularly limited. The length of the target RNA may be, for example, 10 or more residues, 20 or more residues, 50 or more residues, or 100 or more residues, or 10,000 or less residues, 5,000 or less residues, 2,000 or less residues, 1,000 or less residues, or 500 or less residues, or a combination thereof.

[0026] "Expression unit of target RNA" refers to a gene construct that is configured to express a target RNA. The expression unit of target RNA is, in the 5' to 3' direction, a promoter that functions in coryneform bacteria. The promoter sequence includes a base sequence that encodes the target RNA and the target promoter sequence. The base sequence that codes for the target RNA is also called the "gene that codes for the target RNA." The target RNA gene may be linked downstream of a promoter so that the target RNA is expressed under the control of the promoter. The expression unit of the target RNA may be a control sequence (operator) effective for expressing the target RNA in coryneform bacteria. In the present invention, the terms "expression of a target RNA gene", "transcription of a target RNA gene", "expression of a target RNA", and "transcription of a target RNA" can be used synonymously. Expression of a target RNA The unit can be appropriately designed depending on various conditions such as the type of target RNA and the transcription mode.

[0027] The transcription mode of the target RNA is not particularly limited as long as the target RNA can be obtained. For example, the target RNA gene may be transcribed in one direction (i.e., using only one strand of the double strand as a template) or in two directions (i.e., using each strand of the double strand as a template). Bidirectional transcription of the target RNA gene is achieved by using two strands of the target RNA arranged in opposite directions on either side of the gene. This can be achieved by transcribing the gene from a promoter (i.e., a promoter located on the 5' side of the gene on each strand of the double strand). That is, the expression unit of the target RNA may contain two such promoters. In this case, both The promoter may or may not be the same. The target RNA gene is transcribed in one direction. Typically, single-stranded RNA is obtained by transcribing the target RNA gene in both directions. Typically, double-stranded RNA is obtained by transcribing each strand of the double-stranded RNA from a separate expression unit.

[0028] The target RNA gene can be obtained, for example, by cloning. For example, nucleic acids such as genomic DNA or cDNA containing the target RNA gene can be used. The target RNA gene can also be obtained by total synthesis based on the base sequence. (Gene, 60(1), 115-127 (1987)). The obtained target RNA gene can be used as it is or after appropriate modification. The gene can be modified by known techniques. For example, a desired mutation can be introduced into a desired site in DNA by site-directed mutagenesis. Site-specific mutagenesis can be achieved by introducing mutations into the target RNA gene. Examples of site-specific mutagenesis include PCR (Higuchi, R., 61, in PCR technology, Erlich, HA Eds., Stockton press (1989); Carter, P., Meth. in Enzymol., 154, 382 (1987)) and phage (Kramer, W. and Frits, HJ, Meth. in Enzymol., 154, 350 (1987); Kunkel, TA et al., Meth. in Enzymol., 154, 367 (1987)). Alternatively, a mutant of the target RNA gene can be introduced into the target RNA gene by PCR. In addition, a promoter sequence may be appropriately introduced into the obtained target RNA gene. In addition, other components of the expression unit of the target RNA (e.g., promoter sequence) and the entire expression unit of the target RNA can also be obtained. The target RNA gene can be obtained in the same manner as the target RNA gene.

[0029] The promoter for expressing the target RNA gene is any promoter that functions in the host. The term "promoter that functions in a host" refers to a promoter that has promoter activity, i.e., gene transcription activity, in a host. The promoter may be a promoter derived from the host or a heterologous promoter. The promoter may be an intrinsic promoter of the target RNA gene or a promoter of another gene. The promoter may be either inducible or constitutive with respect to the expression of the gene.

[0030] Examples of promoters include promoters of genes involved in glycolysis, the pentose phosphate pathway, the TCA cycle, the amino acid biosynthesis system, and cell surface proteins. In addition, stronger promoters such as those described below may be used as promoters. Stronger promoters include, for example, the artificially engineered P54-6 promoter (Appl. Microbiol. Biotechnolo., 53, 674-679 (2000)), which can be induced by acetate, ethanol, pyruvic acid, etc. pta, aceA, aceB, adh, amyE promoters, other strong promoters such as cspB, SOD, tuf promoters (Journal of Biotechnology 104 (2003) 311-323, Appl Environ Microbiol. 2005 Dec;71(12):8587-96.), lac promoter, tac promoter, trc promoter, F1 promoter, T7 promoter, T5 promoter, T3 promoter, SP6 promoter, Examples of promoters include promoters derived from phages, such as F1 promoter, T7 promoter, T5 promoter, T3 promoter, and SP6 promoter. Examples of promoters include F1 promoter and T7 promoter. The nucleotide sequence of F1 promoter is shown in SEQ ID NO: 13. The nucleotide sequence of T7 promoter is shown in SEQ ID NO: 78.

[0031] As the promoter, a highly active promoter of a conventional promoter may be obtained and used by using various reporter genes. For example, the activity of the promoter can be increased by making the -35 and -10 regions in the promoter region closer to the consensus sequence (WO00 / 18935). Examples of highly active promoters include various tac-like promoters (Katashkina JI et al. Russian Federation Patent application 2006134574) and pnlp8 promoter. A method for evaluating the strength of a promoter and a method for evaluating a strong promoter Examples of motors are described in, for example, Goldstein et al. (Prokaryotic promoters in biotechnology. Biotechnol. Annu. Rev., 1, 105-128 (1995)).

[0032] The promoter may be, for example, a promoter having the nucleotide sequence of the above-exemplified promoter (for example, the nucleotide sequences of SEQ ID NOs: 13 and 78). The promoter may also be a conservative variant of the above-exemplified promoter (for example, the nucleotide sequences of SEQ ID NOs: 13 and 78). That is, for example, the above-exemplified promoters can be used as is or after appropriate modification. The promoters specified by the above promoter names are intended to include the above-exemplified promoters as well as their conservative variants. For example, the term "F1 promoter" is intended to include the promoter having the nucleotide sequence of SEQ ID NO: 13 as well as its conservative variants. For example, the term "T7 promoter" is intended to include the promoter having the nucleotide sequence of SEQ ID NO: 78 as well as its conservative variants. Conservative variants of promoters are described below in relation to the description of conservative variants of ribonuclease III gene. can be applied mutatis mutandis. For example, the promoter may be a promoter having a nucleotide sequence with 80% or more, preferably 90% or more, more preferably 95% or more, even more preferably 97% or more, and particularly preferably 99% or more homology to the nucleotide sequence of SEQ ID NO: 13 or 78, so long as the original function is maintained. The "original function" of a promoter refers to the function of expressing a gene connected immediately downstream thereof under a specified condition. "Under a specified condition" refers to a condition under which the original promoter can express a gene connected immediately downstream thereof. For example, a gene can be constitutively expressed from an F1 promoter. Also, for example, a gene can be expressed by expressing T7 RNA polymerase, T5 RNA polymerase, T3 RNA polymerase, or SP6 RNA polymerase. In the presence of T7, T5, T3, and SP6 promoters, The promoter can be expressed inductively. A conservative variant of a promoter may have, for example, 80% or more, 90% or more, or 100% or more of the transcription activity of the original promoter. The presence or absence and intensity of gene expression (transcription activity) can be confirmed, for example, using a reporter gene.

[0033] A terminator for terminating gene transcription can be placed downstream of the target RNA gene. The terminator is not particularly limited as long as it functions in the host. The terminator may be a terminator derived from the host or a terminator derived from a heterologous species. The terminator may be a terminator inherent to the target RNA gene. Alternatively, the terminator may be a terminator of another gene. A specific example of the terminator is the terminator of bacteriophage BFK20.

[0034] Vectors, promoters, and terminators that can be used in various microorganisms are described in detail in, for example, "Basic Microbiology Lectures 8: Genetic Engineering, Kyoritsu Shuppan, 1987," and they can be used.

[0035] The method for introducing an expression unit of a target RNA into a coryneform bacterium is not particularly limited. "Introduction of an expression unit of a target RNA" refers to having the expression unit of a target RNA retained in a host. Specifically, it may refer to introducing an expression unit of a target RNA into a host so that the gene can be expressed. Unless otherwise specified, "introduction of an expression unit of a target RNA" refers to introduction of a gene of a target RNA into a host that is capable of expressing the gene. It is not limited to the case where the target RNA gene is introduced into the host in a lump. The present invention also includes a case where an expression unit for a target RNA is constructed in a host. The expression unit of the target RNA is present on an extrachromosomal autonomously replicating vector such as a plasmid. The expression unit of the target RNA may be present on a chromosome or may be integrated on a chromosome. That is, the bacterium of the present invention may have, for example, an expression unit of the target RNA on a vector, in other words, a vector containing an expression unit of the target RNA. The bacterium of the present invention may have, for example, an expression unit of the target RNA on a chromosome. The bacterium of the present invention may have only one copy of the expression unit of the target RNA, or may have two or more copies. The copy number of the expression unit of the target RNA possessed by the bacterium of the present invention is, for example, 5 copies / cell or more. The number of copies / cell may be 10 copies / cell or more, 20 copies / cell or more, 30 copies / cell or more, 50 copies / cell or more, 70 copies / cell or more, 100 copies / cell or more, 150 copies / cell or more, 200 copies / cell or more, 300 copies / cell or more, 500 copies / cell or more, or 1000 copies / cell or more, or 2000 copies / cell or less, 1500 copies / cell or less, 1000 copies / cell or less, 500 copies / cell or less, or 300 copies / cell or less, or a compatible combination thereof. The bacterium of the present invention may have only one type of expression unit for a target RNA, or may have two or more types of expression units for a target RNA. The number of copies and type of the expression unit for the target RNA may be, for example, 10 copies / cell or more, 2000 copies / cell or less, 1500 copies / cell or less, 1000 copies / cell or less, 500 copies / cell or less, or 300 copies / cell or less, or a compatible combination thereof. Alternatively, it may be interpreted as the number of copies and type of the target RNA gene. When the bacterium of the present invention has one or more expression units for an RNA of interest, the expression units may be retained in the bacterium so as to be capable of producing the RNA of interest. For example, the expression units may all be retained on a single expression vector, or all may be retained on a chromosome. The expression units may also be retained separately on multiple expression vectors, or may be retained separately on a single or multiple expression vectors and on a chromosome.

[0036] The expression unit of the target RNA can be introduced into a host using, for example, a vector containing the expression unit of the target RNA. A vector containing an expression unit of the target RNA is also called an "expression vector of the target RNA". The expression vector of the target RNA can be constructed, for example, by linking the expression unit of the target RNA to a vector. In addition, for example, when a vector has a promoter that functions in coryneform bacteria, the expression vector of the target RNA can have the target RNA downstream of the promoter. Alternatively, the expression vector can be constructed by linking a target RNA gene to the host. By transforming a host with an expression vector for the target RNA, a transformant into which the vector has been introduced can be obtained, that is, the expression unit for the target RNA can be introduced into the host. A vector capable of autonomously replicating in the cells can be used. The vector is preferably a multicopy vector. The copy number of the vector may be, for example, 5 copies / cell or more, 10 copies / cell or more, 20 copies / cell or more, 30 copies / cell or more, 50 copies / cell or more, 70 copies / cell or more, 100 copies / cell or more, 150 copies / cell or more, 200 copies / cell or more, 300 copies / cell or more, 500 copies / cell or more, or 1000 copies / cell or more, or 2000 copies / cell or less, 1500 copies / cell or less, 1000 copies / cell or less, 500 copies / cell or less, or 300 copies / cell or less, or a compatible combination thereof. In addition, when selecting a transformant, In order to achieve this, it is preferable that the vector has a marker such as an antibiotic resistance gene or an auxotrophy complementing gene. The vector may also have a promoter or terminator for expressing the inserted gene. The vector may be, for example, a bacterial plasmid-derived vector, a yeast plasmid-derived vector, a bacteriophage-derived vector, a cosmid, or a phagemid. Specific examples of vectors capable of autonomous replication in coryneform bacteria include pHM1519 (Agric. Biol. Chem., 48, 2901-2903(1984)); pAM330 (Agric. Biol. Chem., 48, 2901-2903(1984)); and improved versions of these vectors having drug resistance genes. Plasmids: pCRY30 (JP Patent Publication 3-210184); pCRY21, pCRY2KE, pCRY2KX, pCRY31, pCRY3KE pCRY2 and pCRY3 (JP Patent Publication No. 1-191686); pAJ655, pAJ611, and pAJ1844 (JP Patent Publication No. 58-192900); pCG1 (JP Patent Publication No. 57-134500); pCG2 (JP Patent Publication No. 58-35197); pCG4 and pCG11 (JP 57-183799); pPK4 (U.S. Pat. No. 6,090,597); pVK4 (JP 9-322774); pVK7 (JP 10-215883); pVK9 (US2006-0141588); pVC7 (JP 9-070291); and pVS7 (WO2013 / 069634). Specific examples of vectors capable of autonomous replication in coryneform bacteria include pVC7 variants, such as pVC7H1, pVC7H2, pVC7H3, pVC7H4, pVC7H5, pVC7H6, and pVC7H7 (all of which are described in the Examples of the present application). Specific examples of vectors capable of autonomous replication in coryneform bacteria include pPK4 variants, such as pPK4H1, pPK4H2, pPK4H3, pPK4H4, pPK4H5, and pPK4H6 (all of which are described in the Examples of the present application).

[0037] In addition, the expression unit of the target RNA may be, for example, a transposon such as an artificial transposon. When a transposon is used, the expression unit of the target RNA is introduced into the chromosome by homologous recombination or its own transposability. In addition, the expression unit of the target RNA can be introduced into the host chromosome by a method using homologous recombination. The method of introduction using homologous recombination is, for example, linear DNA, temperature-sensitive Examples of such methods include using a plasmid containing a functional replication origin, a conjugatively transferable plasmid, or a suicide vector that does not have a replication origin that functions in the host. Only one copy of the target gene may be introduced, or two or more copies may be introduced. For example, multiple copies of the target RNA expression unit can be introduced into a chromosome by performing homologous recombination targeting a sequence that has multiple copies on a chromosome. Examples of sequences that have copies include repetitive DNA sequences, transposons, etc. Inverted repeats at both ends of the target RNA gene are also included. Alternatively, the target RNA expression unit may be constructed on the chromosome by introducing the target RNA into the chromosome. For example, By introducing the target RNA downstream of the promoter sequence on the host chromosome, It is possible to construct an expression unit for the target RNA. Introduction of a part of an expression unit into a chromosome or introduction of the whole expression unit of a target RNA into a chromosome can be carried out in the same manner.

[0038] The method of transformation is not particularly limited, and commonly used methods such as the protoplast method (Gene, 39, 281-286 (1985)), electroporation method (Bio / Technology, 7, 1067-1070 (1989)), and electric pulse method (JP Patent Publication No. 2-207791) can be used.

[0039] <1-3> Reduction in ribonuclease III activity The bacterium of the present invention has been modified to reduce ribonuclease III (RNase III) activity. Specifically, the bacterium of the present invention has a ribonuclease III activity that is higher than that of a non-modified strain. The RNase III activity is reduced by, for example, In other words, the bacterium of the present invention may be modified, for example, so that the RNase III activity is deleted (eliminated). The coryneform bacteria may be modified to reduce the activity of ribonuclease III. By this, it is possible to improve the ability of the bacterium to produce the target RNA. It is possible to increase the production of the target RNA by bacteria.

[0040] The ribonuclease III and the gene encoding it are described below.

[0041] "Ribonuclease III" is an enzyme that catalyzes the reaction of cleaving specific RNA, such as double-stranded RNA. The gene encoding ribonuclease III is called "ribonuclease III". It is also called the "ase III gene."

[0042] The ribonuclease III gene includes the rnc gene. The protein (ribonuclease III) is also called the "Rnc protein."

[0043] The nucleotide sequences of ribonuclease III genes such as rnc genes possessed by coryneform bacteria and the amino acid sequences of ribonuclease III proteins such as Rnc proteins encoded by them can be obtained from public databases such as NCBI (National Center for Biotechnology Information). The nucleotide sequence of the rnc gene of C. glutamicum ATCC 13869 and the The amino acid sequences of the Rnc proteins are shown in SEQ ID NOs: 51 and 52, respectively. The ribonuclease III gene may be, for example, a gene having the nucleotide sequence of the ribonuclease III gene exemplified above (for example, the nucleotide sequence shown in SEQ ID NO: 51). The ribonuclease III may be, for example, a protein having the amino acid sequence of the ribonuclease III exemplified above (for example, the amino acid sequence shown in SEQ ID NO: 52). Unless otherwise specified, the phrase "a gene or protein has a nucleotide sequence or amino acid sequence" means that the gene or protein contains the nucleotide sequence or amino acid sequence, and also includes cases where the gene or protein consists of the nucleotide sequence or amino acid sequence.

[0044] The ribonuclease III gene can be used in any of the above ribonuclease genes as long as its original function is maintained. A variant of the cleavage gene (e.g., a gene having the base sequence shown in SEQ ID NO:51) Similarly, ribonuclease III may be used as long as its original function is maintained. The above-mentioned ribonuclease III (e.g., the polypeptide having the amino acid sequence shown in SEQ ID NO:52) Such a variant that maintains the original function may be referred to as a "conservative variant." In the present invention, the term "rnc gene" The rnc genes are not limited to the above-mentioned examples, but include conservative variants thereof. Similarly, the term "Rnc protein" is not limited to the Rnc proteins exemplified above, but also includes conservative variants thereof, such as the RNase III genes and RNase III homologs exemplified above, and artificially modified versions.

[0045] "Maintaining the original function" means that the variant of a gene or protein has a function (activity or property) corresponding to the function (activity or property) of the original gene or protein. In other words, "maintaining the original function" means that the variant of the gene or protein has a function (activity or property) corresponding to the function (activity or property) of the original gene or protein. In this case, the term "variant of a gene" refers to a gene that encodes a protein that maintains the original function (i.e., a protein that has RNase III activity). "held" means, in the case of ribonuclease III, that the protein variant is It means having ribonuclease III activity.

[0046] Ribonuclease III activity is determined by inducing the enzyme to react with its substrate RNA (e.g., double-stranded RNA). The activity can be measured by incubating the RNA with a ribozyme and measuring the enzyme-dependent cleavage of RNA. The activity of ribonuclease III is usually measured as follows (Methods Enzymol. 2001;342:143-58.). One example is as follows: 3 This method involves adding an enzyme (e.g., a crude cell extract or a partially purified enzyme thereof) to a synthetic substrate (double-stranded state) of H-labeled poly(AU), reacting at 35°C, treating the reaction solution with trichloroacetic acid, and measuring the degree of decrease in radioactivity in the precipitate fraction (containing high molecular weight nucleic acids) over the reaction time. The activity of ribonuclease III can be calculated by using the degree of reduction in radioactivity as an index of substrate cleavage. Another example is 32 Double-stranded RNA radioactively labeled with P was used as a substrate, which was added to a reaction solution containing the enzyme (30 mM Tris-HCl (pH 8.0), 250 mM potassium glutamate or 160 mM NaCl, 5 mM spermidine, 0.1 mM EDTA, 0.1 mM DTT) and incubated at 37°C for 5 minutes. MgCl2 was added to a final concentration of 10 mM to initiate the RNA degradation reaction. After the reaction had progressed appropriately, an equal volume of EDTA-electrophoresis marker dye mixture (a concentration that results in a final EDTA concentration of 20 mM or more) was added. The reaction is then stopped by adding 7 M urea. Ribonuclease III activity can be detected by subjecting the sample to electrophoresis using a 15% (w / v) denaturing polyacrylamide gel in TBE buffer (89 mM Tris / Tris-borate, 2 mM EDTA) containing 50 mM Tris, and then subjecting the gel to a radiological image analyzer to analyze the degraded RNA fragments.

[0047] Examples of conservative variants are given below.

[0048] The homologue of the RNase III gene or the homologue of RNase III is, for example, the base sequence of the RNase III gene or the base sequence of the RNase III gene. BLAST and FASTA searches were performed using the amino acid sequence of ase III as a query sequence. It can be easily obtained from public databases. Homologs of the above can be prepared by, for example, using the chromosome of a coryneform bacterium as a template and oligonucleotides prepared based on the base sequences of these known ribonuclease III genes or their surrounding regions. It can be obtained by PCR using the primers.

[0049] The ribonuclease III gene can be used in any of the above ribonuclease genes as long as its original function is maintained. In the amino acid sequence of creatinine III (e.g., the amino acid sequence shown in SEQ ID NO:52), It may be a gene encoding a protein having an amino acid sequence in which one or several amino acids at one or several positions have been substituted, deleted, inserted, and / or added. Note that the above-mentioned "one or several" varies depending on the position of the amino acid residue in the three-dimensional structure of the protein and the type of amino acid residue, but specifically means, for example, 1 to 50, 1 to 40, 1 to 30, preferably 1 to 20, more preferably 1 to 10, even more preferably 1 to 5, and particularly preferably 1 to 3.

[0050] The above-mentioned substitution, deletion, insertion, and / or addition of one or several amino acids is a conservative mutation that maintains the normal function of the protein. A representative conservative mutation is a conservative substitution. When the substitution site is an aromatic amino acid, a conservative substitution is between Phe, Trp, and Tyr. If the substitution site is a hydrophobic amino acid, it is preferred to use Leu, Ile, or Val, which is a polar amino acid. In the case of a basic amino acid, it is between Gln and Asn, and in the case of an acidic amino acid, it is between Lys, Arg, and His. In the case of amino acids, it is a mutation that substitutes Asp and Glu, and in the case of amino acids having a hydroxyl group, it is a mutation that substitutes Ser and Thr. Conservative substitutions are specifically, for example, substitutions of Ala with Ser or Thr, substitutions of Arg with Gln, His or Lys, substitutions of Asn with Glu, etc. , substitution of Gln, Lys, His or Asp, substitution of Asp with Asn, Glu or Gln, substitution of Cys with Ser or Ala, substitution of Gln with Asn, Glu, Lys, His, Asp or Arg, substitution of Glu with Gly, Asn, Gln, Lys or Asp, substitution of Gly with Pro, substitution of His with Asn, Lys, Gln, Arg or Tyr, substitution of Ile with Leu, Met, Val or Phe, substitution of Leu with Ile, Met, Val or Phe, substitution of Lys to Asn, Glu, Gln, His, or Arg; Met to Ile, Leu, Val, or Phe; Examples of such substitutions, deletions, insertions, or additions include substitutions of Val with Trp, Tyr, Met, Ile, or Leu, substitutions of Ser with Thr or Ala, substitutions of Thr with Ser or Ala, substitutions of Trp with Phe or Tyr, substitutions of Tyr with His, Phe, or Trp, and substitutions of Val with Met, Ile, or Leu. The above-mentioned amino acid substitutions, deletions, insertions, or additions also include those that arise due to naturally occurring mutations (mutants or variants) based on individual differences or species differences in the bacteria from which the genes are derived.

[0051] In addition, the RNase III gene may be used in any of the above-mentioned embodiments as long as its original function is maintained. It is preferable that the amino acid sequence of RNase III is 80% or more, preferably 90% or more, more preferably 100% or more. Preferably, the homology is 95% or more, more preferably 97% or more, and particularly preferably 99% or more. It may be a gene encoding a protein having an amino acid sequence similar to that of the target gene. In this specification, "homology" means "identity."

[0052] In addition, the RNase III gene may be used in any of the above-mentioned embodiments as long as its original function is maintained. Complement of the nucleotide sequence of the RNase III gene (e.g., the nucleotide sequence shown in SEQ ID NO:51) The term "stringent conditions" refers to conditions under which a specific hybridization reaction can be performed. For example, DNAs with high homology, for example, DNAs with a homology of 80% or more, preferably 90% or more, more preferably 95% or more, even more preferably 97% or more, and particularly preferably 99% or more, are hybridized. DNA that is less homologous than the one that is not hybridized with each other, or The washing conditions for Southern hybridization described above include washing once, and preferably two to three times, at a salt concentration and temperature corresponding to 60°C, 1 x SSC, 0.1% SDS, preferably 60°C, 0.1 x SSC, 0.1% SDS, and more preferably 68°C, 0.1 x SSC, 0.1% SDS.

[0053] The above-mentioned probe may be, for example, a part of the complementary sequence of a gene. Such a probe can be prepared by PCR using oligonucleotides prepared based on the base sequence of a known gene as primers and a DNA fragment containing these base sequences as a template. As the probe, for example, a DNA fragment having a length of about 300 bp can be used. In such a case, In this case, washing conditions for hybridization include 50° C., 2×SSC, and 0.1% SDS.

[0054] In addition, since the degeneracy of codons varies depending on the host, the ribonuclease III gene may be In other words, the RNase III gene may be a variant of the above-mentioned RNase III genes due to the degeneracy of the genetic code.

[0055] The percentage of sequence identity between two sequences can be determined, for example, using a mathematical algorithm. Non-limiting examples of such mathematical algorithms include the algorithm of Myers and Miller (1988) CABIOS 4:11-17, the local homology algorithm of Smith et al (1981) Adv. Appl. Math. 2:482, the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443-453, the method of searching for similarity of Pearson and Lipman (1988) Proc. Natl. Acad. Sci. 85:2444-2448, and the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264, with modifications as described in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877.

[0056] Using programs based on these mathematical algorithms, sequence comparison (alignment) for determining sequence identity can be performed. The programs can be executed by a computer as appropriate. Such programs include, but are not limited to, CLUSTAL (available from Intelligenetics, Mountain View, Calif.) and ALIGN programs (Version 2.0) of the PC / Gene program, and GAP, BESTFIT, BLAST, FASTA, and TFASTA of the Wisconsin Genetics Software Package, Version 8 (available from Genetics Computer Group (GCG), 575 Science Drive, Madison, Wis., USA). Alignment using these programs can be performed, for example, using default parameters. The CLUSTAL program has been described in detail in Higgins et al. (1988) Gene 73:237-244, Higgins et al. (1989) CABIOS 5:151-153, Corpet et al. (1988) Nucleic Acids Res. 16:10881-90, Huang et al. (1992) CABIOS 8:155-65, and Pearson et al. (1994) Meth. Mol. Biol. 24:307-331.

[0057] To obtain nucleotide sequences that are homologous to a nucleotide sequence encoding a protein of interest, a BLAST nucleotide search can be performed, for example, using the BLASTN program, score = 100, word length = 12. Amino acids with homology to the target protein To obtain sequences, specifically, for example, a BLAST protein search can be performed using the BLASTX program, A score of 50 and word length of 3 can be used for BLAST nucleotide searches and BLAST protein searches. For quality searches, see http: / / www.ncbi.nlm.nih.gov. For comparative purposes, To obtain gapped alignments as PSI-BLAST can also be used to perform an iterative search that detects distant relationships between sequences. For Gapped BLAST and PSI-BLAST, see Altschul et al. (1997) Nucleic Acids Res. 25:3389. When using BLAST, Gapped BLAST, or PSI-BLAST, for example, the default parameters of the respective programs (e.g., BLASTN for nucleotide sequences, BLASTX for amino acid sequences) can be used. Alignments may also be performed manually.

[0058] The sequence identity between two sequences is calculated as the percentage of matching residues between the two sequences when the two sequences are aligned for maximum correspondence.

[0059] The above descriptions regarding gene and protein variants can also be applied mutatis mutandis to any other proteins or target RNAs, and the genes that encode them.

[0060] Below are some methods to reduce the activity of proteins (enzymes) such as RNase III. He explains.

[0061] "The activity of a protein is reduced" means that the activity of the protein is reduced as compared to a non-modified strain. "The activity of a protein is reduced" specifically means that the activity of the protein per cell is reduced as compared to a non-modified strain. "Non-modified strain" here refers to a control strain that has not been modified to reduce the activity of the target protein. Examples of non-modified strains include wild-type strains and parent strains. Examples of non-modified strains include type strains of each bacterial species. Examples of non-modified strains include Corynebacterium tuberculosis, Corynebacterium tuberculosis, and Corynebacterium tuberculosis. The strains exemplified in the description of the type bacteria are also included. That is, in one embodiment, the activity of the protein may be reduced compared to the reference strain (i.e., the reference strain of the species to which the bacterium of the present invention belongs). In another embodiment, the activity of the protein may be reduced compared to the C. glutamicum ATCC 13032 strain. In another embodiment, the activity of the protein may be reduced compared to the C. glutamicum 2256 strain (ATCC 13869). Note that "the activity of the protein is reduced" also includes the case where the activity of the protein is completely lost. More specifically, "the activity of the protein is reduced" may mean that the number of molecules of the protein per cell is reduced and / or the function of the protein per molecule is reduced compared to the non-modified strain. That is, the "activity" in "the activity of the protein is reduced" is not limited to the catalytic activity of the protein, but may also mean the transcription amount (mRNA amount) or translation amount (protein amount) of the gene encoding the protein. Note that "the number of molecules of the protein per cell is reduced" also includes the case where the protein is completely absent. In addition, "the function per molecule of a protein is reduced" also includes the case where the function per molecule of the protein is completely lost. The degree of reduction in protein activity is not particularly limited as long as the activity of the protein is reduced compared to that of a non-modified strain. The activity of the protein may be reduced to, for example, 50% or less, 20% or less, 10% or less, 5% or less, or 0% of that of a non-modified strain.

[0062] A modification that reduces the activity of a protein can be achieved, for example, by reducing the expression of a gene that encodes the protein. It means that the expression of the gene is decreased compared to a non-modified strain. "Decreased gene expression" specifically means that the expression level of the gene per cell is decreased compared to a non-modified strain. "Decreased gene expression" may more specifically mean that the transcription level (mRNA level) of the gene is decreased and / or the translation level (protein level) of the gene is decreased. "Decreased gene expression" also includes cases where the gene is not expressed at all. "Decreased gene expression" is also referred to as "weakened gene expression." Gene expression may be decreased to, for example, 50% or less, 20% or less, 10% or less, 5% or less, or 0% of that of a non-modified strain.

[0063] The reduction in gene expression may be due to, for example, a reduction in transcription efficiency, a reduction in translation efficiency, or a combination thereof. The reduction in gene expression can be achieved, for example, by modifying an expression regulatory sequence such as a gene promoter, a Shine-Dalgarno (SD) sequence (also called a ribosome binding site (RBS)), or a spacer region between the RBS and the start codon. When modifying an expression regulatory sequence, the expression regulatory sequence is modified preferably by one or more bases, more preferably two or more bases, and particularly preferably three or more bases. The reduction in gene transcription efficiency can be achieved, for example, by replacing a promoter of a gene on a chromosome with a weaker promoter. The term "weaker promoter" refers to a promoter that weakens the transcription of a gene compared to the wild-type promoter that is originally present. An example of a weaker promoter is an inducible promoter. That is, an inducible promoter can function as a weaker promoter under non-inducing conditions (for example, in the absence of an inducer). In addition, a part or all of the expression regulatory sequence may be deleted. In addition, the reduction in gene expression can also be achieved, for example, by manipulating factors involved in expression control. Factors involved in expression control include small molecules (inducers, inhibitors, etc.), proteins (transcription factors, etc.), and nucleic acids (siRNA, etc.) involved in transcription and translation control. In addition, a decrease in gene expression can be caused by, for example, This can also be achieved by introducing a mutation that reduces gene expression. For example, gene expression can be reduced by replacing codons in the coding region of the gene with synonymous codons that are used less frequently in the host. In addition, gene expression itself can be reduced by, for example, disrupting the gene as described below.

[0064] Modifications that reduce the activity of a protein can be achieved, for example, by disrupting the gene that codes for the protein. "The gene is disrupted" means that the gene is modified so that it does not produce a protein that functions normally. "Not producing a protein that functions normally" includes cases where no protein is produced from the gene at all, and cases where the gene produces a protein with reduced or lost function (activity or properties) per molecule.

[0065] The destruction of a gene can be achieved, for example, by deleting (deleting) the gene on a chromosome. "Deletion of a gene" refers to the deletion of a part or the whole region of the coding region of a gene. Furthermore, the whole gene may be deleted, including the sequences before and after the coding region of the gene on a chromosome. The region to be deleted may be any region, such as the N-terminal region (the region coding the N-terminal side of a protein), an internal region, or a C-terminal region (the region coding the C-terminal side of a protein), as long as the activity of the protein can be reduced. In general, the longer the region to be deleted, the more reliably the gene can be inactivated. The region to be deleted may be, for example, a region with a length of 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, or 95% or more of the entire length of the coding region of the gene. In addition, it is preferable that the sequences before and after the region to be deleted do not match in reading frame. A mismatch in reading frame may cause a frameshift downstream of the region to be deleted.

[0066] Gene disruption can also be achieved, for example, by introducing an amino acid substitution (missense mutation) into the coding region of a gene on a chromosome, introducing a stop codon (nonsense mutation), or introducing an addition or deletion of 1 to 2 bases (frameshift mutation) (Journal of Biological Chemistry 272:8611-8617(1997), Proceedings of the National Academy of Sciences, USA 95 5511-5515(1998), Journal of Biological Chemistry 26 116, 20833-20839(1991)).

[0067] Gene disruption can also be achieved, for example, by inserting another base sequence into the coding region of the gene on the chromosome. The insertion site may be any region of the gene, but the longer the base sequence to be inserted, the more reliably the gene can be inactivated. In addition, it is preferable that the sequences before and after the insertion site do not match in reading frame. A mismatch in reading frame may cause a frame shift downstream of the region to be deleted. The other base sequence is not particularly limited as long as it reduces or eliminates the activity of the encoded protein, and examples of such sequences include marker genes such as antibiotic resistance genes and genes useful for producing target substances.

[0068] The gene may be disrupted so that the amino acid sequence of the encoded protein is deleted. In other words, the modification to reduce the activity of the protein can be achieved, for example, by deleting the amino acid sequence of the protein, specifically by modifying the gene so as to code for a protein with the deleted amino acid sequence. The term "deletion of the amino acid sequence of the protein" refers to the deletion of a part or all of the region of the amino acid sequence of the protein. The term "deletion of the amino acid sequence of the protein" refers to the absence of the original amino acid sequence in the protein, and also includes the case where the original amino acid sequence is changed to another amino acid sequence. That is, for example, a region that has been changed to another amino acid sequence by frameshift may be considered as the deleted region. The deletion of the amino acid sequence of the protein typically shortens the full length of the protein, but there may be cases where the full length of the protein does not change or is extended. For example, the deletion of a part or all of the coding region of the gene can delete the region encoded by the deleted region in the encoded protein. For example, by introducing a stop codon into the coding region of a gene, the region coded by the region downstream of the introduction site can be deleted in the encoded protein. For example, by frameshifting in the coding region of a gene, the region coded by the frameshift site can be deleted in the encoded protein. The position and length of the region to be deleted in the deletion of an amino acid sequence can be determined mutatis mutandis from the explanation of the position and length of the region to be deleted in the deletion of a gene.

[0069] The above-mentioned modification of a gene on a chromosome can be carried out, for example, by preparing a disrupted gene that is modified so as not to produce a protein that functions normally, and then carrying out the modification using recombinant DNA containing the disrupted gene. This can be achieved by transforming the host and inducing homologous recombination between the disrupted gene and the wild-type gene on the chromosome, thereby replacing the wild-type gene on the chromosome with the disrupted gene. In this case, the recombinant DNA contains a marker gene according to the host's characteristics such as nutritional requirements. Inclusion of the gene in the gene makes it easier to handle in experimental procedures. Disrupted genes include genes in which all or part of the gene has been deleted, genes containing missense mutations, genes containing nonsense mutations, genes containing frameshift mutations, and genes into which transposons or marker genes have been inserted. Even if a protein encoded by a disrupted gene is produced, it has a three-dimensional structure different from that of the wild-type protein, and its function is reduced or lost. Gene disruption by gene replacement using such homologous recombination has already been established, and is known as "Red The Red-driven integration method combines the Red-driven integration method with an excision system derived from λ phage (Cho, EH, Gumport, RI, Gardner, JFJ Bacteriol. 184: 5200-5203 (2002)) and is called "Red-driven integration" (Datsenko, K. A, and Wanner, BL Proc. Natl. Acad. Sci. US A. 97:6640-6645 (2000)). There are methods using linear DNA such as the method (see WO2005 / 010175), methods using a plasmid containing a temperature-sensitive replication origin, methods using a conjugatively transferable plasmid, and methods using a suicide vector that does not have a replication origin that functions in the host (U.S. Pat. No. 6,303,383, Japanese Patent Application Publication No. 05-007491).

[0070] Furthermore, a modification that reduces the activity of a protein may be performed, for example, by a mutation treatment. Examples of the mutation treatment include irradiation with X-rays, irradiation with ultraviolet light, and N-methyl-N' Examples of such mutagens include treatment with mutagens such as N-nitro-N-nitrosoguanidine (MNNG), ethyl methanesulfonate (EMS), and methyl methanesulfonate (MMS).

[0071] The above-mentioned methods for reducing the activity of a protein may be used alone or in any combination.

[0072] In addition, when a protein functions as a complex consisting of multiple subunits, all of the multiple subunits may be modified, or only a part of them may be modified, as long as the activity of the protein is reduced as a result. That is, for example, all of the multiple genes encoding the subunits may be disrupted, or only a part of them may be disrupted, or the like. In addition, when a protein has multiple isozymes, the activities of all of the multiple isozymes may be reduced, or only a part of them may be reduced, as long as the activity of the protein is reduced as a result. That is, for example, all of the multiple genes encoding the isozymes may be disrupted, or only a part of them may be disrupted, or the like.

[0073] The decrease in the activity of a protein can be confirmed by measuring the activity of the protein.

[0074] A decrease in protein activity can also be confirmed by confirming a decrease in expression of the gene encoding the protein. A decrease in gene expression can be confirmed by confirming a decrease in the transcription level of the gene or a decrease in the amount of the protein expressed from the gene.

[0075] The reduction in the amount of gene transcription can be confirmed by comparing the amount of mRNA transcribed from the gene with that of a non-modified strain. Methods for evaluating the amount of mRNA include northern hybridization, RT-PCR, microarrays, and RNA-seq (Molecular Cloning(Cold Spring Harbor Laboratory Press, Cold Spring Harbor (USA), 2001) The amount of mRNA (e.g., the number of mRNA molecules per cell) may be reduced to, for example, 50% or less, 20% or less, 10% or less, 5% or less, or 0% of that of an unmodified strain.

[0076] The reduction in the amount of the protein can be confirmed by Western blotting using an antibody (Molecular Cloning (Cold Spring Harbor Laboratory Press, Cold Spring Harbor (USA), 2001)). The amount of the protein (e.g., the number of protein molecules per cell) may be reduced to, for example, 50% or less, 20% or less, 10% or less, 5% or less, or 0% of that of a non-modified strain.

[0077] Depending on the means used for the disruption, gene disruption can be confirmed by determining the nucleotide sequence, restriction enzyme map, or full length of a part or all of the gene.

[0078] The above-mentioned methods for reducing the activity of proteins are limited to reducing the activity of ribonuclease III. The present invention can be used to reduce the activity of any protein and the expression of any gene.

[0079] <2> Methods of the Invention The bacterium of the present invention obtained as described above can be used to produce target RNA. The method of the present invention comprises culturing the bacterium of the present invention in a medium and harvesting the transcribed target RNA. The present invention relates to a method for producing a target RNA, the method comprising: culturing the bacterium of the present invention in a medium; In other words, the method of the present invention specifically comprises culturing the bacterium of the present invention in a medium, and accumulating the target RNA in the bacterium. and collecting the target RNA from the bacterial cells.

[0080] The bacterium of the present invention can be cultured under culture conditions commonly used for culturing bacteria such as coryneform bacteria. The bacterium of the present invention can be cultured in a conventional medium containing, for example, a carbon source, a nitrogen source, and inorganic ions. Furthermore, organic micronutrients such as vitamins and amino acids can be added as necessary.

[0081] Examples of carbon sources that can be used include carbohydrates such as glucose and sucrose, organic acids such as acetic acid, alcohols, and the like. Examples of nitrogen sources that can be used include ammonia gas, ammonia water, ammonium salts, and the like. Examples of inorganic ions that can be used appropriately as needed include calcium ions, magnesium ions, phosphate ions, potassium ions, and iron ions. The culture is carried out for 10 to 120 hours under aerobic conditions, for example, at a pH of 5.0 to 8.5 and in the appropriate range of 15°C to 37°C. It is also possible to refer to the culture conditions for L-amino acid production by bacteria such as coryneform bacteria and the culture conditions for secretory production of proteins by bacteria such as coryneform bacteria (WO01 / 23591, WO2005 / 103278, WO2013 / 065869, WO2013 / 065772, WO2013 / 118544, WO2013 / 062029, etc.). When an inducible promoter is used for expressing the target RNA, the expression of the target RNA can be appropriately induced.

[0082] By culturing the bacterium of the present invention under such conditions, the target RNA is transcribed and expressed intracellularly. Accumulates in.

[0083] The expression and accumulation of the target RNA can be confirmed by, for example, electrophoresis of a fraction containing a bacterial extract as a sample. This can be confirmed by performing electrophoresis and detecting a band corresponding to the molecular weight of the target RNA. can.

[0084] The target RNA can be recovered from the cells by any suitable method for isolating and purifying the compound. Examples of such techniques include centrifugation, salting out, ethanol precipitation, ultrafiltration, gel filtration chromatography, ion exchange chromatography, affinity chromatography, and electrophoresis. These techniques may be used alone or in appropriate combination. Specifically, for example, the cells are disrupted by ultrasonic waves or the like, and the cells are removed by centrifugation or the like, from which the target RNA is recovered by an ion exchange resin method or the like. The target RNA to be recovered may be in the free form, a salt thereof, or a mixture thereof. The target RNA to be recovered may be a complex with a polymer compound such as a protein. That is, the term "target RNA" in the present invention may refer to the target RNA in a free form, a salt thereof, a complex of the target RNA with a polymeric compound such as a protein, or a mixture thereof. Examples of the salt include ammonium salts and sodium salts.

[0085] The recovered target RNA may contain, in addition to the target RNA, components such as bacteria, medium components, water, and metabolic by-products of bacteria. The target RNA may be purified to a desired degree. The purity of the recovered target RNA may be, for example, 30% (w / w) or more, 50% (w / w) or more, 70% (w / w) or more, 80% (w / w) or more, 90% (w / w) or more, or 95% (w / w) or more. EXAMPLES

[0086] The present invention will be described in more detail below with reference to examples, but the present invention is not limited thereto.

[0087] <1> Isolation of a mutant lacking the ribonuclease III gene from Corynebacterium glutamicum Ribonucleic acid fragments of C. glutamicum strain 2256 (ATCC13869 strain, hereinafter also referred to as "strain 2256") were A disruptant of the RNaseIII homologue gene (hereinafter also referred to as "rnc gene") was constructed as follows.

[0088] First, based on the amino acid sequence homology with known RNase III, we assumed that the region present at REGION: 2115207..2115950 in the genome sequence information (Accession No. AP017557) of C. glutamicum 2256 strain in the gene database (GenBank) was the rnc gene. Therefore, the information required to delete the gene was the ORF (open reading frame) region. The DNA sequence information of the region and its upstream and downstream regions, each of which is about 1,000 bases (1 kb), is The sequences were obtained from the GenBank database.

[0089] Next, genomic DNA was obtained from the 2256 strain using the DNeasy Blood & Tissue Kit (QIAGEN). Using this genomic DNA as a template, a DNA fragment containing approximately 1 kb of the upstream region of the rnc gene was amplified using primers of SEQ ID NO: 1 and 2, and a DNA fragment containing approximately 1 kb of the upstream region of the rnc gene was amplified using primers of SEQ ID NO: 3 and 4. DNA fragments containing approximately 1 kb of the downstream region were obtained by PCR amplification using PrimeSTAR GXL DNA Polymerase (TAKARA BIO). The PCR conditions were in accordance with the manufacturer's recommended protocol. These DNA fragments were then ligated to the plasmid pBS4S (WO2005 / 113745 and WO2005 / 113744; not replicable in C. glutamicum) carrying the sacB gene, using the following procedure. Specifically, pBS4S was used as a template, and primers of SEQ ID NOs: 5 and 6 were used to clone PrimeSTAR GXL DNA. Polymerase was used for PCR amplification to obtain the amplified fragment of pBS4S. Next, both the upstream and downstream DNA fragments of the rnc gene obtained above were mixed with the amplified fragment of pBS4S, and the mixture was incubated with In-Fusion HD The three fragments were ligated using the Cloning Kit (Clontech) (Figure 1). The reaction mixture was used to transform competent cells of Escherichia coli JM109 strain (TAKARA BIO). The resulting plasmid was applied to an LB agar medium containing 25 μg / ml kanamycin and cultured overnight at 37°C. A single colony was then isolated from the colonies that appeared on the agar medium to obtain a kanamycin-resistant transformant. Plasmids were extracted from the resulting transformant by standard methods. A plasmid containing the DNA fragments of the ribosomal region and the downstream region was identified by structural analysis and named pBS4SΔrnc. We named it (Figure 1).

[0090] Since this plasmid cannot replicate autonomously in coryneform bacteria, when this plasmid is introduced into coryneform bacteria, the plasmid is integrated into the chromosome by genetic homologous recombination, and transformants that show kanamycin resistance appear, although at very low frequency. Therefore, the 2256 strain was transformed with a high concentration of the plasmid pBS4Δrnc by the electric pulse method, and the transformed strain was incubated with 25 μg / ml kanamycin. CM-Dex agar medium (glucose 5g / L, polypeptone 10g / L, yeast extract The medium was then spread onto a plate containing 10 g / L glycerol, 1 g / L KH2PO4, 0.4 g / L MgSO4·7H2O, 0.01 g / L FeSO4·7H2O, 0.01 g / L MnSO4·7H2O, 3 g / L urea, 1.2 g / L soybean hydrolysate, pH 7.5 (adjusted with KOH), and 20 g / L agar, and cultured overnight at 30°C. As a result, several colonies appeared. The strains grown on this medium had undergone homologous recombination between a DNA sequence fragment near the rnc gene of the plasmid (upstream or downstream region) and a region near the rnc gene on the genome of the 2256 strain, resulting in the insertion of the plasmid into the genome. This is a so-called single recombinant strain, in which the kanamycin resistance gene and sacB gene derived from the plasmid have been inserted.

[0091] Next, these single recombinants were cultured overnight at 30°C in CM-Dex medium without kanamycin (same composition as CM-Dex agar medium except that it does not contain agar). The culture solution was appropriately diluted and then cultured on Dex-S10 agar medium containing 10% (w / v) sucrose without kanamycin (sucrose). 100g / L, polypeptone 10g / L, yeast extract 10g / L, KH2PO4 1g / L, MgSO4 The mixture was spread onto agar (0.4g / L FeSO4·7H2O, 0.01g / L FeSO4·7H2O, 0.01g / L MnSO4·4H2O, 3g / L urea, 1.2g / L soybean hydrolysate, 10μg / L biotin, pH 7.5 (adjusted with KOH), 20g / L agar) and cultured overnight at 30℃. As a result, several colonies appeared. These strains were considered to have become sucrose insensitive due to the loss of the sacB gene by the second homologous recombination. The strains obtained in this way included those in which the rnc gene had been replaced by a defective type and those in which it had reverted to the wild type. The colonies that emerged were subjected to colony PCR using KOD FX NEO (TOYOBO) to select rnc gene-deficient strains. As a result of analyzing the length of the rnc gene region of these strains, it was found that the length of the DNA fragment in PCR amplification was shorter than that of the genomic DNA of the 2256 strain (wild type) as a template. Therefore, one of the strains was selected as an rnc gene-deficient strain and named 2256Δrnc. The length of the PCR-amplified DNA fragment in the case of the gene was approximately 3 kbp, and the length of the PCR-amplified DNA fragment in the case of the deleted rnc gene was approximately 2 kbp (Figure 2).

[0092] <2> Curing of endogenous plasmids The 2256 strain has an endogenous plasmid, pAM330 (Yamaguchi, Ryuji, et al. "Determination of the complete nucleotide sequence of Brevibacterium lactofermentum plasmid pAM330"). pAM330 and analysis of its genetic information." Agricultural and biological chemistry 50.11 (1986): 2771-2778.) The sacB gene was carried on the plasmid pVC7 (JP Patent Publication 1997-070291). A plasmid carrying the construct pVC7-sacB was constructed. pVC7 is a plasmid carrying pAM330 and This is a composite plasmid of the general-purpose vector pHSG399 (manufactured by TAKARA BIO). The primers shown in SEQ ID NO: 9 and 10 were used with pBS4S as a template to generate PrimeSTAR GXL DNA. Polymerase was used to amplify the sacB gene. In addition, pVC7 was used as a template, and primers shown in SEQ ID NOs: 11 and 12 were used to amplify the sacB gene using KOD FX NEO (TOYOBO). The two amplified fragments were mixed and ligated to each other using the In-Fusion HD Cloning Kit (Clontech). Next, this reaction solution was used to transform the E. coli JM109 strain. The competent cells (manufactured by TAKARA BIO) were transformed, spread onto LB agar medium containing 25 μg / ml chloramphenicol, and cultured overnight at 37°C. Then, single colonies were isolated from the colonies that appeared. Plasmids were extracted from the transformants thus obtained by standard methods, and DNA sequence analysis was performed. The desired plasmid was identified and named pVC7-sacB (Figure 3). pVC7-sacB was introduced into the 2256Δrnc and 2256Δrnc strains by electric pulse method, and the strains were plated on CM-Dex agar medium containing 5 μg / ml chloramphenicol and cultured overnight at 30 ° C., and several transformants of the 2256 / pVC7-sacB strain and the 2256Δrnc / pVC7-sacB strain were obtained. Then, from among them, the 2256ΔpAM330 / pVC7-sacB strain and the 2256ΔrncΔpAM330 / pVC7-sacB strain in which the endogenous plasmid pAM330 had been removed were obtained. Furthermore, these strains were plated on Dex-S10 agar medium and cultured overnight at 30 ° C., and the 2256ΔpAM330 strain and the 2256ΔrncΔpAM330 strain in which pVC7-sacB had been removed and which had become sucrose insensitive were obtained.

[0093] <3> Construction of plasmid pVC7-Pf1-U1Ainsert for unidirectional transcription The plasmid pVC7-Pf1-U1Ainsert for unidirectional transcription of the U1A binding sequence as the target RNA under the control of the F1 promoter was constructed as follows.

[0094] The promoter sequence derived from bacteriophage BFK20, which infects coryneform bacteria (Accession No. The promoter region (SEQ ID NO: 13; hereafter referred to as F1 promoter; Koptides, M., et al., (1992). Characterization of bacteriophage BFK20 from Brevibacterium flavum. Microbiology, 138(7), 1387-1391.) and the terminator (ter) region (SEQ ID NO: 14; Bukovska, G., et al., (2006). Complete nucleotide sequence and genome analysis of bacteriophage BFK20-a lytic phage of the industrial producer Brevibacterium flavum. Virology, 348(1), 57-71) of the target RNA were added to the siRNA. The siRNA was further added to the siRNA. The siRNA was further added to the siRNA. The siRNA was further added to the siRNA. Mediate d by a cell-permeant RNA-binding protein and photoinduced RNA interference. Bioconjugate chemistry, 19(5), 1017-1024.) was selected, and the DNA sequence of the transcription unit of the U1A binding sequence (U1Ainsert RNA transcription unit; SEQ ID NO: 16) was designed (Figure 4). The DNA fragment of the transcription unit was prepared by chemical synthesis (Eurofins Genomics). Next, using the DNA fragment as a template, primers of sequence numbers 17 and 18 were used to perform PCR amplification using KOD FX NEO (TOYOBO) to obtain an amplified fragment of the U1A insert RNA transcription unit. Also, using pVC7 as a template, primers of sequence numbers 19 and 20 were used to perform PCR amplification using KOD FX NEO (TOYOBO) to obtain an amplified fragment of pVC7. These amplified fragments were then mixed and ligated to each other using an In-Fusion HD Cloning Kit (Clontech). Next, competent cells of Escherichia coli JM109 strain (TAKARA BIO) were transformed with this reaction solution, and chloramphenicol was added to the ligated cells. The plasmid was spread on LB agar medium containing 25 μg / ml Nicol and cultured overnight at 37°C. Then, single colonies were isolated from the colonies that emerged to obtain transformants. Plasmids were extracted from the resulting transformants by standard methods. The desired plasmid was identified by DNA sequence analysis and named pVC7-Pf1-U1Ainsert (Figure 4).

[0095] <4> Construction of plasmid pVC7-Pf1-Hv-iap-Pf1rev for bidirectional transcription A plus for bidirectional transcription of Hv-iap RNA as the target RNA under the control of the F1 promoter. The plasmid pVC7-Pf1-Hv-iap-Pf1rev was constructed as follows.

[0096] A DNA fragment of Hv-iap (SEQ ID NO: 21), which is a partial sequence of cDNA derived from the iap gene encoding the apoptosis inhibitor IAP derived from Coccinellidae 2010-spotted ladybird beetle, was chemically synthesized based on the information described in WO2010 / 140675. A plasmid containing a DNA sequence in which the Hv-iap sequence was linked immediately after the F1 promoter was constructed as follows (FIG. 5A). First, pVC7 was used as a template. As a template, primers of sequence numbers 20 and 22 were used and PCR was performed using KOD FX NEO (TOYOBO). The DNA fragment of pVC7 was amplified by PCR using the DNA fragment of SEQ ID NO: 16 as a template and primers of SEQ ID NO: 23 and 24 with PrimeSTAR HS (manufactured by TAKARA BIO). A DNA fragment containing the Hv-iap sequence was obtained. In addition, the DNA fragment of SEQ ID NO: 21 was used as a template, and primers of SEQ ID NO: 25 and 26 were used to amplify the DNA fragment with the Hv-iap sequence using PrimeSTAR HS (manufactured by TAKARA BIO). These three fragments were then mixed and amplified using the In-Fusion HD Cloning Kit. The DNA fragments were ligated using a PCR kit (Clontech). Competent cells of the JM109 strain (manufactured by TAKARA BIO) were transformed with chloramphenicol 25 A resistant strain was obtained at 1 μg / ml. Plasmids were extracted from the resulting transformants by a conventional method. DNA The plasmids of interest were identified by sequence analysis, and one of them was named pVC7-Pf1-Hv-iap. The results were reported (Figure 5A).

[0097] Using pVC7 as a template and primers of SEQ ID NO:20 and 27, PCR amplification was performed with KOD FX NEO (TOYOBO) to obtain a DNA fragment of pVC7. Primers 28 and 29 were used for PCR amplification using PrimeSTAR HS (TAKARA BIO). The amplified fragment of the F1 promoter sequence was obtained. The two amplified fragments were mixed and ligated using the In-Fusion HD Cloning Kit (Clontech). Next, this reaction solution was used to transform the Escherichia coli JM109 strain. The competent cells (manufactured by TAKARA BIO) were transformed, spread on LB agar medium containing 25 μg / ml chloramphenicol, and cultured overnight at 37°C. Then, a single colony was isolated from the colonies that appeared. Plasmids were extracted from the resulting transformants by standard methods. DNA sequence analysis The desired plasmid was identified by PCR analysis and named pVC7-Pf1rev (Figure 5B).

[0098] Next, restriction enzyme sites KpnI and XhoI were inserted downstream of the F1 promoter of pVC7-Pf1rev. To introduce the nucleotide sequence, pVC7-Pf1rev was used as a template and primers with sequence numbers 20 and 30 were used. Then, inverse PCR was performed using the KOD-Plus-Mutagenesis Kit (TOYOBO). The amplified DNA fragment was then subjected to DpnI treatment, phosphorylation, and self-ligation to obtain the circular DNA fragment. The vector was transformed into a competent cell of Escherichia coli JM109 strain (TAKARA BIO). The cells were spread on LB agar medium containing 25 μg / ml chloramphenicol and cultured overnight at 37°C. Single colonies were then isolated from the colonies that appeared. Plasmids were extracted from the resulting transformants by standard methods. The plasmids of interest were identified by DNA sequence analysis and The vector was designated pVC7-KpnI-XhoI-Pf1rev (Figure 5B).

[0099] Next, using pVC7-Pf1-Hv-iap as a template and primers of sequence numbers 31 and 32, PCR was performed using PrimeSTAR HS (manufactured by TAKARA BIO) to obtain a DNA fragment containing the KpnI restriction enzyme site-F1 promoter region-Hv-iap region-XhoI restriction enzyme site in that order. This DNA fragment and pVC7-KpnI-XhoI-Pf1rev were cut with the restriction enzymes KpnI and XhoI, respectively, and purified with a MinElute PCR Purification Kit (manufactured by Qiagen). The two purified products were mixed and linked together by a ligation reaction using Ligation high Ver.2 (manufactured by TOYOBO). Next, this reaction solution was used to Competent cells of the JM109 strain of Escherichia coli (TAKARA BIO) were transformed with chloramphenicol. A strain resistant to 25 μg / ml of phenylalanine was obtained. Plasmids were extracted from the resulting transformants by standard methods. The desired plasmid was identified by DNA sequence analysis and named pVC7-Pf1-Hv-iap-Pf1rev (Figure 5B).

[0100] <5> Production of target RNA The pVC7, pVC7-Pf1-U1Ainsert, and pVC7-Pf1-Hv-iap-Pf1rev plasmids were transfected into C. glutamicum 2256ΔpAM330 and C. glutamicum 2256ΔrncΔpAM330 strains by electroporation. The cells were then transferred to a CM-Dex agar medium containing 5 μg / ml chloramphenicol and incubated at 30°C for 1 h. The transformants 2256ΔpAM330 / pVC7 and 2256ΔrncΔpAM330 / pVC7 were isolated and cultured overnight. , 2256ΔpAM330 / pVC7-Pf1-U1Ainsert strain, 2256ΔrncΔpAM330 / pVC7-Pf1-U1Ainsert strain, 2256ΔpAM330 / pVC7-Pf1-Hv-iap-Pf1rev strain, and 2256ΔrncΔpAM330 / pVC7-Pf1-Hv-iap-Pf1rev strain were obtained, respectively.

[0101] The colonies of each transformant obtained above were cultured on CM-Dex agar medium (chloramphenicol 5 The cultured bacteria were then spread onto a plate containing 1 μg / ml of lysozyme and cultured at 30°C for approximately 16 hours. A portion of the cultured bacteria was then used for test tube culture. The culture was cultured for 24 hours at 30°C with shaking in CM-Dex medium (2 ml) containing chloramphenicol (5 μg / ml). Then, 200 μl of the culture was treated with RNAprotect Bacteria Reagent and the supernatant was removed. Next, 225 μl of TE buffer containing 15 mg / ml of lysozyme (Sigma) was added and reacted at room temperature for 30 minutes, and 25 μl of 20 mg / mL proK (TAKARA BIO) was added. The mixture was incubated at room temperature for 30 minutes and then washed with TRIzol LS (Thermo Fisher Scientific) The extracted RNA was dissolved in 50 μl of RNase-free water and A total RNA solution was prepared. The total RNA solution obtained was subjected to total RNA analysis using Novex TBE Gels, 6% (Thermo Fisher Scientific). 1 μl of each total RNA solution was applied to a lane of the gel, and polyacrylamide gel electrophoresis (PAGE) was carried out under non-denaturing conditions.

[0102] As a result, when comparing the total RNA extracted from the 2256ΔpAM330 / pVC7-Pf1-U1Ainsert strain and the 2256ΔrncΔpAM330 / pVC7-Pf1-U1Ainsert strain, only the strain lacking the rnc gene showed the expected Similarly, the RNA band derived from the U1A insert was confirmed at the position where the U1A insert was located (Figure 6). Even when comparing total RNA, the Hv-iap-derived RNA band was confirmed at the expected position only in the strain lacking the rnc gene (Figure 6). Therefore, the lack of the rnc gene is a factor in the development of the Corynebacterium genus. It was shown to be effective for RNA production using bacteria.

[0103] <6> Obtaining high copy number plasmids Sixty clones of 2256 / pVC7 transformants were cultured overnight in CM-Dex medium containing chloramphenicol (5 μg / ml). 500 μl of the culture medium was centrifuged (14,400 × g, 2 min) to recover the cells, which were then immersed in 100 mL of lysozyme (Sigma Aldrich) derived from chicken egg white dissolved at 15 mg / ml in P1 buffer (Qiagen). Then, 200 μl of QIAprep Spin Miniprep Kit (manufactured by QIAprep) was added and reacted at 37°C for 30 minutes. Plasmids were extracted from the cells of each clone using Qiagen and subjected to agarose electrophoresis to compare the amount of plasmid. As a result, the amount of plasmid extracted from one clone was larger than that of the other clones. It was observed that the DNA bands were clearly thicker than those extracted from the clones. The plasmid was then introduced into the 2256 strain, and the plasmid was extracted from the transformant in the same manner, and the yield was analyzed by agarose gel electrophoresis. As above, the plasmid showed a clearly thicker DNA band than the control pVC7, i.e., the plasmid was the same as the original plasmid. It was found that this plasmid was maintained at a higher copy number in the cells of coryneform bacteria than the plasmid pVC7, and this plasmid was named pVC7H1.

[0104] The mutation site of the obtained pVC7H1 was analyzed using a DNA sequencer Genetic Analyzer 3500xl (Applied Biosystems). As a result, it was revealed that in pVC7H1, the 1172nd base (the second base A from the 5' end of the cleavage recognition site of the restriction enzyme HindIII is +1) of the total base sequence of pVC7 (6679 bp) was substituted from cytosine (C) to adenine (A). Hereinafter, this mutation will be referred to as "C1172A". Therefore, it was revealed that this mutation is the cause of the high copy number of pVC7H1.

[0105] Since it was revealed that the C1172A mutation significantly increased the copy number of pVC7, the mutations in this region listed in Table 1 were each introduced into pVC7 to evaluate their effect on the copy number of the plasmid.

[0106] Each mutant plasmid was constructed using the KOD-Plus-Mutagenesis Kit (Toyobo Co., Ltd.). Using the plasmid pVC7 as a template, pVC7H2 was constructed using primers of SEQ ID NOs: 33 and 34, pVC7H3 was constructed using primers of SEQ ID NOs: 33 and 35, pVC7H4 was constructed using primers of SEQ ID NOs: 36 and 37, pVC7H5 was constructed using primers of SEQ ID NOs: 36 and 38, pVC7H6 was constructed using primers of SEQ ID NOs: 33 and 39, and pVC7H7 was constructed using primers of SEQ ID NOs: 33 and 40 (Table 1). The complete nucleotide sequence was confirmed to be correct using a DNA sequencer. .

[0107] [Table 1]

[0108] Each constructed plasmid was transformed into the 2256ΔpAM330 strain by a standard method. CM-Dex agar medium containing chloramphenicol (5 μg / ml) was used as the selection medium. When any plasmid was transformed, colonies were formed well. Therefore, colonies carrying each plasmid were inoculated into the same agar medium using a platinum loop and cultured at 30°C for about one day. Then, the grown bacterial bodies (approximately 2 cm square) of each strain were inoculated into CM-Dex medium containing chloramphenicol (5 mg / L) and cultured overnight with shaking at 30°C.

[0109] The plasmids contained in the culture were extracted from the culture medium by a conventional method. A portion of the prepared plasmid solution was subjected to agarose electrophoresis, and the DNA bands of each plasmid were analyzed. The results are shown in Table 2. .

[0110] [Table 2]

[0111] As a result, mutant plasmids with a clearly higher copy number than the initially obtained pVC7H1 were obtained. One of them, pVC7H2, was used in the subsequent experiments. The copy number of pVC7 is thought to be about 10 copies / cell, that of pVC7H1 about 100 copies / cell, and that of pVC7H2 about 250 copies / cell.

[0112] <7> RNA production using high copy number plasmids High copy number versions of pVC7-Pf1-U1Ainsert and pVC7-Pf1-Hv-iap-Pf1rev were constructed as follows. Specifically, inverse PCR was performed using pVC7-Pf1-U1Ainsert or pVC7-Pf1-Hv-iap-Pf1rev as a template and primers of SEQ ID NOs: 33 and 41 for pVC7H1 mutagenesis or primers of SEQ ID NOs: 33 and 34 for pVC7H2 mutagenesis with the KOD-Plus-Mutagenesis Kit (TOYOBO). The resulting DNA fragment was then subjected to DpnI treatment, phosphorylation, and self-ligation to circularize it, and the resulting DNA fragment was then inserted into the competent Escherichia coli JM109 strain. Tocell (manufactured by TAKARA BIO) was transformed. The cells were spread on LB agar medium containing chloramphenicol (25 μg / ml) and cultured overnight at 37°C. Single colonies were isolated from the colonies that appeared. Plasmids were extracted from the resulting transformants by standard methods. DNA sequence analysis revealed that The desired plasmids were identified and designated pVC7H1-Pf1-U1Ainsert, pVC7H2-Pf1-U1Ainsert, pVC7H1-Pf1-Hv-iap-Pf1rev, and pVC7H2-Pf1-Hv-iap-Pf1rev.

[0113] Next, the pVC7, pVC7-Pf1-U1Ainsert, pVC7H1-Pf1-U1Ainsert, pVC7H2-Pf1-U1Ainsert, pVC7-Pf1-Hv-iap-Pf1rev, pVC7H1-Pf1-Hv-iap-Pf1rev, and pVC7H2-Pf1-Hv-iap-Pf1rev plasmids were introduced into the 2256ΔrncΔpAM330 strain by electric pulse method, and the resulting mixture was plated on CM-Dex agar medium containing chloramphenicol (5 μg / ml) and cultured overnight at 30°C. As a result, the following transformants were obtained: 2256ΔrncΔpAM330 / pVC7 strain, 2256ΔrncΔpAM330 / pVC7-Pf1-U1Ainsert strain, 2256ΔrncΔpAM330 / pVC7H1-Pf1-U1Ainsert strain, 2256ΔrncΔpAM330 / pVC7H2-Pf1-U1Ainsert strain, 2256ΔrncΔpAM330 / pVC7-Pf1-Hv-iap-Pf1rev strain, 2256ΔrncΔpAM330 / pVC7H1-Pf1-Hv-iap-Pf1rev strain, and 2256ΔrncΔpAM330 / pVC7H2-Pf1-Hv-iap-Pf1rev strain. The transformants were cultured in test tubes and the RNA produced by each strain was evaluated. A portion of the bacteria cultured on the agar medium was transferred to CM-Dex medium containing chloramphenicol (5 μg / ml). The bacteria were inoculated into 200 μl of culture medium and cultured at 30°C for 24 hours with shaking. RNA was then extracted from 200 μl of culture medium using the same procedure as in the above example, including treatment with RNAprotect Bacteria Reagent, and the RNA sample was finally dissolved in 50 μl of RNase-free water to prepare a total RNA solution. The total RNA solution obtained was subjected to PAGE analysis under non-denaturing conditions using Novex TBE Gels (6%). - Total RNA analysis was performed. As a result, the accumulation levels of U1Ainsert-RNA increased in the order of pVC7-Pf1-U1Ainsert << pVC7H1-Pf1-U1Ainsert ≒ pVC7H2-Pf1-U1Ainsert (Figure 7). Similarly, the accumulation levels of Hv-iap-dsRNA also increased in the order of pVC7-Pf1-Hv-iap-Pf1rev <<< pVC7H1-Pf1-Hv-iap-Pf1rev < pVC7H2-Pf1-Hv-iap-Pf1rev (Figure 7). From this, it was shown that increasing the copy number of the RNA transcription plasmid increased the intracellular accumulation level of the target RNA. It was shown that increasing the copy number of the RNA transcription plasmid increased the intracellular accumulation level of the target RNA.

[0114] <8>Comparison with RNA production by the T7 promoter-inducible expression system in E. coli As previously reported (Timmons, L., Court, D. L., & Fire, A. (2001). Ingestion of bacterially expressed dsRNAs can produce specific and potent genetic interference in Caenorhabditis elegans. Gene, 263(1), 103-112.), an RNA production system using T7 RNA polymerase has been reported in the Escherichia coli HT115(DE3) strain, which is an rnc gene-deficient strain. Therefore, RNA production by the F1 promoter expression system in the C. glutamicum 2256ΔrncΔpAM330 strain was compared with RNA production by the T7 promoter-inducible expression system in E. coli. For this purpose, the plasmid pL4440-Pt7-U1Ainsert for transcribing the U1A binding sequence unidirectionally under the control of the T7 promoter and the plasmid pL4440-Pt7-Hv-iap-Pt7rev for bidirectionally transcribing Hv-iap RNA under the control of the T7 promoter were constructed according to the following procedure.

[0115] For this purpose, the plasmid pL4440-Pt7-U1Ainsert for transcribing the U1A binding sequence unidirectionally under the control of the T7 promoter and the plasmid pL4440-Pt7-Hv-iap-Pt7rev for bidirectionally transcribing Hv-iap RNA under the control of the T7 promoter were constructed according to the following procedure. For this purpose, the plasmid pL4440-Pt7-U1Ainsert for transcribing the U1A binding sequence unidirectionally under the control of the T7 promoter and the plasmid pL4440-Pt7-Hv-iap-Pt7rev for bidirectionally transcribing Hv-iap RNA under the control of the T7 promoter were constructed according to the following procedure.

[0116] Using the plasmid pL4440 (GE Healthcare) as a template, PCR was performed with primers of SEQ ID NOs: 42 and 43 on KOD FX NEO to obtain a DNA fragment of pL4440. Also, using pVC7-Pf1-U1Ainsert as a template, PCR was performed with primers of SEQ ID NOs: 44 and 45 on PrimeSTAR HS (TAKARA BIO) to obtain a DNA fragment containing the U1Ainsert sequence. Also, a DNA strand of SEQ ID NO: 46 and a DNA strand of SEQ ID NO: 47 (the DNA strand of SEQ ID NO: 47 has a sequence corresponding to the complementary sequence of the DNA strand of SEQ ID NO: 46) were isolated. The PCR products were mixed and annealed together, and purified using the MinElute PCR Purification Kit. These three DNA fragments were mixed and ligated to each other using the In-Fusion HD Cloning Kit. Competent cells of E. coli JM109 strain were transformed, spread on LB agar medium containing ampicillin (100 μg / ml), and cultured overnight at 37°C. Single colonies were then isolated from the colonies that appeared. Plasmids were extracted from the resulting transformants by standard methods. The desired plasmids were identified, one of which was named pL4440-Pt7-U1Ainsert. (Figure 8).

[0117] Using the plasmid pL4440 as a template and primers of SEQ ID NOs: 42 and 48, KOD FX PCR was performed using NEO to obtain a DNA fragment of pL4440. <9> PCR was performed using primers of SEQ ID NO: 49 and 50 with KOD FX NEO, using the template (described later in (2-2)), to obtain a DNA fragment of the "Pt7-Hv-iap-Pt7rev" region. These DNA fragments were mixed and ligated to each other using the In-Fusion HD Cloning Kit. Next, competent cells of Escherichia coli JM109 strain were transformed with this reaction solution, spread on LB agar medium containing ampicillin (100 μg / ml), and cultured overnight at 37 °C. Then, a single colony was isolated from the colonies that appeared. Plasmids were extracted from the obtained transformants by conventional methods. The target plasmids were identified by DNA sequence analysis, and one of them was named pL4440-Pt7-Hv-iap-Pt7rev (Figure 9).

[0118] pL4440-Pt7-U1Ainsert or pL4440-Pt7-Hv-iap-Pt7rev was introduced into E. coli HT115(DE3) strain by electric pulse method to obtain the transformants HT115(DE3) / pL4440-Pt7-U1Ainsert strain and HT115(DE3) / pL4440-Pt7-Hv-iap-Pt7rev strain. These strains were shake-cultured overnight at 37°C in LB liquid medium containing ampicillin (100 μg / ml) in a test tube to prepare a seed culture solution. Next, the seed culture solution was added to the LB liquid medium containing ampicillin (100 μg / ml) in a volume of 1 / 50, and main culture was started at 37°C. After shaking culture for about 3 hours, the final concentration of 1 mM was obtained. IPTG was added at 4, 8, and 24 hours after the addition of IPTG, and the culture was continued. Samples were taken at 4, 8, and 24 hours after the addition of IPTG. 200 μl of the culture medium was centrifuged at 13,800×g for 2 minutes to collect the cells. RNA was extracted using a ELISA kit (manufactured by Fisher Scientific) according to the protocol, and dissolved in 50 μl of RNase-free water to prepare a total RNA solution. <7> in The total RNA solution of C. glutamicum obtained was used. PAGE was performed under non-denaturing conditions using 1 μl of each RNA sample and Novex TBE Gels (6%). As a result, the F1 progeny of C. glutamicum was The amount of U1Ainsert-ssRNA produced by the F1 promoter expression system was greater than that produced by the T7 promoter inducible expression system in E. coli (Figure 10). Similarly, the amount of Hv-iap-dsRNA produced by the F1 promoter expression system in C. glutamicum was greater than that produced by the T7 promoter inducible expression system in E. coli (Figure 10). The amount of Hv-iap-dsRNA produced was greater than that produced by the promoter-inducible expression system (FIG. 10). Therefore, it was demonstrated that coryneform bacteria such as C. glutamicum are useful for producing target RNA.

[0119] <9> RNA production using a T7 promoter-inducible expression system in C. glutamicum (1) Preparation of hairpin RNA (1-1) Construction of plasmid pPK-T7lac-vd-antiOlac for transcription of hairpin RNA The plasmid pPK-T7lac-vd-antiOlac for unidirectional transcription of a hairpin RNA as a target RNA under the control of the T7 promoter was constructed as follows.

[0120] (1-1-1) Construction of pUC57-VD Based on the genome sequence of Potato spindle tuber viroid (PSTVd).125 (Mol Biol (Mosk). 2013 Jan-Feb;47(1):94-106.), a DNA fragment of SEQ ID NO:53 encoding a hairpin RNA was prepared by chemical synthesis. This DNA fragment was cloned into pUC57 (ATG Service-Gen, St. Petersburg, Russia) to construct pUC57-VD.

[0121] (1-1-2) Construction of pPK-T7lac First, the T7 terminator (T T7 A fragment (131 bp) containing the nucleotide sequence 144 of the present invention was amplified from pET22b(+) (Novagen). This fragment was then digested with KpnI and SalI and cloned into pPK4 (US Patent 6,090,597) linearized with the same restriction enzymes. The constructed plasmid was used as pPK4XB - This was named T7 ter (Figure 11).

[0122] Next, the lacI-P T7 -Olac-MCS-T T7 Another fragment (1959 bp) containing the DNA region of was amplified from pET22b(+). This amplified fragment was digested with KpnI. pPK4 XB - The plasmid was cloned into T7 ter and named pPK-T7lac (Figure 12).

[0123] (1-1-3) Construction of pPK-T7lac-vd-antiOlac The DNA fragment VD-aOlac was excised from pUC57-VD using XbaI and XhoI and cloned into pPK-T7lac using T4 DNA ligase. The ligation mixture was transformed into competent cells of E. coli strain LE392 (Promega) by electroporation. Standard electroporation procedures for E. coli cells were performed. The cells were grown at 37°C for 1.5 h and then plated on LB agar plates supplemented with 50 μg / ml kanamycin (Km) to elucidate the kanamycin resistance (Km r ) transformants were obtained. Plasmids were extracted from the transformants, and the desired plasmid was selected and named pPK-T7lac-vd-antiOlac (Figure 13).

[0124] (1-2) Construction of plasmid pVC54-T7Pol for expressing T7 RNA polymerase The plasmid pVC54-T7Pol for expressing T7 RNA polymerase was constructed as follows.

[0125] (1-2-1) Construction of pVC54 To construct pVC54, the region of SEQ ID NO:58 of pVC7 (U.S. Patent 5,804,414) (chloramphenicol resistance (Cm r ) gene promoter region and pAM330-derived region) are The region was replaced with a region containing a strong promoter by the procedure described above.

[0126] DNA fragment-A (161 bp) of SEQ ID NO:58, which contains a strong promoter, was prepared by chemical synthesis. DNA fragment-B was amplified by PCR using primers of SEQ ID NO:60 (L54-Cm) and 61 (R55-Cm) with pVC7 plasmid as a template. Barrapping PCR was performed, and the resulting PCR fragment was divided into two fragments, SEQ ID NO: 62 (L54-hpa) and The amplified fragment was then amplified again by PCR using primer 61(R55-Cm). The resulting plasmid was digested with HpaI and NcoI and ligated into the HpaI-NcoI sites of pVC7. The ligation mixture was transformed into competent cells of E. coli strain TG1 (Zymo Research), and Cm r The transformants were obtained. Plasmids were extracted from the transformants, and the desired plasmid was selected and named pVC54. (Figure 14).

[0127] (1-2-2) Construction of pBS5t-ptrB*-T7pol The genomic DNA of strain 2256 was used as a template, and primers of SEQ ID NO: 63 (x550) and 64 (x551) were used. A DNA fragment (2021 bp) containing the ptrB gene and a part of the hemH gene was amplified by PCR using The amplified fragment was digested with BglII and cloned into the BamHI site of pBS5t (WO2006 / 057450). The resulting plasmid was named pBS5t-ptrB* (Figure 15). Contains a unique NheI site in a portion of the gene.

[0128] In addition, pAH162-λattL-Tc R -The rrnB terminator was amplified by PCR using λattR (BMC Biotechnology 2008, 8:63) as a template and primers of SEQ ID NO: 65 (x553) and 66 (x554). Another DNA fragment (531 bp) containing the nucleotide sequence (TrrnB) and the L3 terminator (tL3) was amplified. The fragment was digested with NheI and cloned into the NheI site of pBS5t-ptrB*. The plasmid was designated pBS5t-ptrB*-2Ter (Figure 16). This plasmid contains a unique BamHI site between the terminators TrrnB and tL3, and both terminators are flanked by BglII sites.

[0129] Finally, the DNA fragment (4452 bp) containing lacI-PlacUV5-gene1 was transformed into pAR1219 (Proc The lacI-PlacUV5-gene1 fragment was excised from pBS5t-ptrB*-2Ter (Natl Acad Sci U S A. 1984 Apr; 81(7): 2035-2039) and cloned into the unique BamHI site of pBS5t-ptrB*-2Ter. The lacI-PlacUV5-gene1 fragment was amplified by the T7 RNA polymerase. It contains gene1, which encodes the lacUV5 gene and is expressed under the control of the lacUV5 promoter (PlacUV5). A plasmid in which the pGamma gene was oriented toward tL3 was selected and designated pBS5t-ptrB*-T7pol (Figure 17).

[0130] (1-2-3) Construction of pVC54-T7pol The plasmid pVC54-T7Pol for expressing T7 RNA polymerase was constructed from pVC54 and pBS5t-ptrB*-T7pol as follows.

[0131] First, a DNA fragment containing lacI-PlacUV5-gene1 was excised from pBS5t-ptrB*-T7pol using BglII. This DNA fragment was then ligated into the BamHI site of pVC54 to construct pVC54-T7pol (Figure 18).

[0132] (1-3) Construction of RNA-producing C. glutamicum First, C. glutamicum 2256ΔrncΔpAM330 was transformed with pVC54-T7Pol by electrotransformation. The transformants were grown in CM2G medium (5 g / L of glucose, 10 g / L of tryptone, 10 g / L of yeast extract, 5 g / L of NaCl, pH adjusted to 7.0) supplemented with 10 μg / mL chloramphenicol (Cm). ) at 30°C for 24 hours, and transformants were selected. Then, single colony isolation was performed to obtain two independent clones of C. glutamicum 2256ΔrncΔpAM330 carrying pVC54-T7Pol. These two clones were further transformed with pPK-T7lac-vd-antiOlac. The transformants were grown for 24 hours at 30°C in CM2G medium supplemented with 10 μg / mL Cm and 25 μg / ml Km, and transformants were selected. Single colony isolation was performed again to obtain two independent clones (designated clones A and B) of C. glutamicum 2256ΔrncΔpAM330 carrying pVC54-T7Pol and pPK-T7lac-vd-antiOlac (designated C. glutamicum 2256ΔrncΔpAM330 / pVC54-T7Pol / pPK-T7lac-vd-antiOlac).

[0133] (1-4) RNA production using T7 promoter-inducible expression system in C. glutamicum C. glutamicum 2256ΔrncΔpAM330 / pVC54-T7Pol / pPK-T7lac-vd-antiOlac strains (clone A and B, respectively) were inoculated into 5 ml of CM2G medium supplemented with 10 μg / mL Cm and 25 μg / ml Km. The following morning, the same strain was transferred to the same fresh medium (5 ml) and grown at OD 600 Value is 0.2 to 0.3 The bacteria were inoculated so that the total volume was 100 ml and cultured at 32°C for 4 to 5 hours. At this point, induction was performed by adding 2 mM IPTG to the culture. After induction, the culture was continued for an additional 3 and 19 hours, and the culture OD of the solution 600 Then, 1–2 ml of the culture was immediately mixed with RNAprotect Bacteria Reagent (QIAGEN 76506) as recommended by the manufacturer, and the bacterial pellet was immediately frozen at −70°C.

[0134] All samples were thawed at 4°C and subjected to RNA isolation using Trizol LS (Ambion 10296028). The isolated total RNA was diluted with 30 μl of DEPC-treated water to prepare a total RNA solution, and the RNA concentration in the solution was measured using a Nanodrop spectrophotometer. A portion of the solution was then denatured. The total RNA was subjected to urea PAGE (5%). Typically, 3 μg of each total RNA solution was applied to each well of the gel. After electrophoresis, the RNA in the gel was stained with ethidium bromide (EthBr). As a result, the target RNA band (VD related RNAs) was observed in the IPTG-induced sample (Figure 19). In other words, RNA production by the T7 promoter-inducible expression system in C. glutamicum was confirmed.

[0135] (2) Production of Hv-iap RNA (2-1) Construction of plasmid pPK4-T7pol for expressing T7 RNA polymerase The plasmid pPK4-T7pol for expressing T7 RNA polymerase was constructed as follows.

[0136] Using pVC54-T7pol as a template, primers of SEQ ID NOs: 67 and 68 and KOD FX NEO polymerase A DNA fragment containing gene 1 (T7pol), which encodes T7 RNA polymerase, was isolated by PCR using the The plasmid pPK4 (U.S. Patent 6,090,597) was amplified. Another DNA fragment was amplified by PCR using the primers. The resulting fragments were ligated to each other using the On HD Cloning Kit (TAKARA BIO). The reaction mixture was then transformed into competent cells of E. coli JM109 and plated on LB agar medium containing Km (50 μg / mL). , and incubated at 37°C for 16 hours. R Among them, several colonies were isolated. The plasmid was isolated from the transformant and the plasmid was extracted. After confirming the DNA sequence of the plasmid, The plasmid was selected and named pPK4-T7pol (Figure 20).

[0137] (2-2) Construction of plasmid pVC7-Pt7-Hv-iap-Pt7rev for transcription of Hv-iap RNA A plus for bidirectional transcription of Hv-iap RNA as the target RNA under the control of the T7 promoter. The plasmid pVC7-Pt7-Hv-iap-Pt7rev was constructed as follows.

[0138] (2-2-1) Construction of pVC7-Pt7-KpnI-XhoI-Pt7rev Using pVC7 as a template, PCR was performed using primers of SEQ ID NOs: 71 and 72 and KOD FX NEO. DNA fragment-N was amplified. DNA fragment-P of SEQ ID NO: 73 (containing a T7 promoter (forward), a KpnI restriction site, an XhoI restriction site, and a T7 promoter (reverse) in this order) and another DNA fragment-Q of SEQ ID NO: 74 (containing a complementary sequence of fragment-P) were prepared by chemical synthesis. The two single-stranded DNA fragments were mixed and annealed to produce DNA fragment-R. Then, DNA fragment-N and DNA fragment-R were ligated to each other using the In-Fusion HD Cloning Kit. The mixture was transformed into competent cells of E. coli JM109, spread onto LB agar medium containing Cm (25 μg / ml), and cultured at 37°C for 16 hours to obtain Cm. R Among them, several transformants were obtained. Ronnie was isolated and the plasmid was extracted from the transformant. After confirming the DNA sequence of the plasmid, The desired plasmid was selected and named pVC7-Pt7-KpnI-XhoI-Pt7rev (Figure 21).

[0139] (2-2-2) Construction of pVC7-Pt7-Hv-iap-Pt7rev DNA fragment-S (containing a KpnI restriction site, an Hv-iap site, and an XhoI restriction site, in that order) was amplified by PCR using the DNA fragment of SEQ ID NO: 75 as a template and the primers of SEQ ID NO: 76 and 77. Then, DNA fragment-S and pVC7-Pt7-KpnI-XhoI-Pt7rev were amplified using KpnI and XhoI, respectively. The resulting fragments were digested with 500 kDa and purified with the MinElute PCR Purification Kit (Qiagen). The two purified fragments were mixed and ligated to each other using Ligation high ver. 2 (TOYOBO). Competent cells of E. coli JM109 were transformed with the reaction mixture, spread on LB agar medium containing Cm (25 μg / ml), and incubated at 37°C for 16 h. Cultivated for 3 hours R Among them, several colonies were isolated and the phenotypes were analyzed. Plasmids were extracted from the transformants. After confirming the DNA sequence of the plasmid, the desired plasmid was The plasmid selected was designated pVC7-Pt7-Hv-iap-Pt7rev (Figure 21).

[0140] (2-3) Construction of RNA-producing C. glutamicum Create the C. glutamicum 2256ΔrncΔpAM330 strain with pPK4-T7pol by electroporation. The bacterial cell suspension was spread on a CM-Dex agar medium containing Km (25 μg / ml) and incubated at 30°C for 16 hours. The transformants were obtained by culturing for 1 h. Then, pVC7-Pt7-Hv-iap-Pt7rev was introduced into one of the transformants. The cell suspension was spread on CM-Dex agar medium containing Km (25 μg / ml) and Cm (5 μg / ml). The transformants were obtained by culturing at 30° C. for 24 hours, and finally, C. glutamicum 2256ΔrncΔpAM330 / pPK4-T7pol / pVC7-Pt7-Hv-iap-Pt7rev was obtained.

[0141] (2-4) RNA production using T7 promoter-inducible expression system in C. glutamicum C. glutamicum 2256ΔrncΔpAM330 / pPK4-T7pol / pVC7-Pt7-Hv-iap-Pt7rev was grown in a test tube in CM-Dex medium containing Km (25 μg / ml) and Cm (5 μg / ml) at 30°C for 16 hours to prepare a seed culture. The seed culture was then added to fresh CM-Dex medium at 1 / 10 the volume, and main culture was started at 30°C. After 6 hours of culture, a portion of the culture was sampled, and 2 mM IPTG was added to the remaining part of the culture for further culture. 3 and 27 hours after the addition of IPTG, the culture A portion of the solution was sampled. RNA was extracted from 200 μl of the culture medium by the same procedure as in 1., and the RNA sample was finally diluted with 50 mL of RNase-free water. The RNA was dissolved in 1 μl of PBS to prepare a total RNA solution.

[0142] Each total RNA solution was applied to a Novex TBE gel (6%) and RNA production was analyzed. As a result, the target RNA band (Hv-iap RNA) was observed in the sample obtained 27 hours after IPTG induction. In other words, RNA production by the T7 promoter-inducible expression system in C. glutamicum was confirmed again.

[0143] <10> Obtaining high copy number plasmid of pPK4 Plasmid pPK4 is a composite plasmid of plasmid pHSG399 available in E. coli and plasmid pHM1519 available in C. glutamicum ATCC 13058; It functions as a shuttle vector capable of replicating in the

[0144] Each of the mutations shown in Table 3 was introduced into pPK4, and the effect on the copy number of the plasmid was evaluated.

[0145] Each mutant plasmid was constructed using the KOD-Plus-Mutagenesis Kit (Toyobo Co., Ltd.). Using the plasmid pPK4 as a template, pPK4H1 was constructed using primers of SEQ ID NOs: 79 and 80, pPK4H2 was constructed using primers of SEQ ID NOs: 81 and 82, pPK4H3 was constructed using primers of SEQ ID NOs: 83 and 82, pPK4H4 was constructed using primers of SEQ ID NOs: 84 and 82, pPK4H5 was constructed using primers of SEQ ID NOs: 85 and 82, and pPK4H6 was constructed using primers of SEQ ID NOs: 86 and 82 (Table 3). The complete nucleotide sequence was confirmed to be correct using a DNA sequencer. .

[0146] [Table 3]

[0147] The copy number of the constructed plasmid is shown in Example <5> As a result, all of the mutant plasmids of pPK4 shown in Table 3 showed higher copy numbers in C. glutamicum than the original plasmid pPK4. Among them, pPK4H1 showed the highest copy number, and its The number of copies reached about 200 or more per host chromosome.

[0148] <11> RNA production using pPK4H1 The U1A-RNA expression system was incorporated into the plasmid pPK4H1 by the following procedure.

[0149] Using pVC7-Pf1-U1Ainsert as a template, an amplified fragment of the U1Ainsert RNA transcription unit was obtained by PCR amplification using primers of SEQ ID NOs: 87 and 88 and KOD FX NEO (TOYOBO). Also, using pPK4H1 as a template, an amplified fragment of pPK4H1 was obtained by PCR amplification using primers of SEQ ID NOs: 89 and 90 and KOD FX NEO (TOYOBO). These amplified fragments were mixed and ligated to each other using In-Fusion HD Cloning Kit (Clontech). Next, the reaction mixture was used to transform E. coli JM109 competent cells (TAKARA BIO), and the resulting products were grown on LB agar medium containing 50 μg / mL kanamycin. The mixture was applied to a medium and cultured overnight at 37°C. Then, a single colony was separated from the colonies that appeared to obtain a transformant. Plasmids were extracted from the resulting transformant by a conventional method. The desired plasmid was identified by sequence analysis and designated pPK4H1-Pf1-U1Ainsert.

[0150] Plasmids pPK4H1 and pPK4H1-Pf1-U1Ainsert were introduced into C. glutamicum strain 2256ΔrncΔpAM330 by electroporation, and the resulting cultures were plated on CM-Dex agar containing 25 μg / mL kanamycin. The mixture was spread on a medium and cultured overnight at 30° C. As a result, the transformants 2256ΔrncΔpAM330 / pPK4H1 and 2256ΔrncΔpAM330 / pPK4H1-Pf1-U1Ainsert were obtained.

[0151] Two colonies were selected from each transformant and incubated on CM-Dex medium containing 25 μg / mL kanamycin. The culture was applied to a 30°C medium and cultured at 30°C for about 16 hours. A portion of the cultured cells was then used for test tube culture. The cells were cultured with shaking at 30°C for 24 hours in CM-Dex medium (2 ml) containing 25 μg / mL kanamycin. Then, 200 μl of the culture medium was treated with RNAprotect Bacteria Reagent, and the supernatant was removed. Next, 225 μl of TE buffer containing 15 mg / ml lysozyme (Sigma) was added and incubated at room temperature. The mixture was incubated at room temperature for 30 minutes at 4°C for 30 minutes, and then 25 μl of 20 mg / mL proK (manufactured by TAKARA BIO) was added and incubated at room temperature for 30 minutes. RNA was then extracted using TRIzol LS (manufactured by Thermo Fisher Scientific). The extracted RNA was dissolved in 50 μl of RNase-free water to prepare a total RNA solution. The total RNA solution was then washed with Novex TBE Gels, 6% (Thermo Fisher Scientific). Total RNA analysis was performed using a 100-μL gel (Impact Biosciences, Inc.). That is, 1 μl of each total RNA solution was applied to a gel lane, and subjected to polyacrylamide gel electrophoresis under non-denaturing conditions. PAGE was performed.

[0152] As a result, the U1Ainsert-derived RNA band was confirmed at the expected position only in the 2256ΔrncΔpAM330 / pPK4H1-Pf1-U1Ainsert strain (FIG. 23). Therefore, even when a pHM1519-derived vector different from the pVC7-derived vector used in the previous Example was used, a large amount of target RNA could be successfully produced using Corynebacterium bacteria as a host. [Industrial Applicability]

[0153] According to the present invention, RNA can be produced efficiently.

[0154] <Description of sequence listing> SEQ ID NOs: 1 to 12: Primers SEQ ID NO: 13: Nucleotide sequence of F1 promoter SEQ ID NO: 14: Base sequence of the terminator region of BFK20 SEQ ID NO: 15: Nucleotide sequence of U1A binding sequence SEQ ID NO: 16: Nucleotide sequence of U1A insert RNA transcription unit SEQ ID NOs: 17 to 20: primers SEQ ID NO: 21: Nucleotide sequence of Hv-iap SEQ ID NOs: 22 to 50: primers SEQ ID NO: 51: Nucleotide sequence of the rnc gene of C. glutamicum 2256 (ATCC 13869) SEQ ID NO: 52: Amino acid sequence of the Rnc protein of C. glutamicum 2256 (ATCC 13869) SEQ ID NO: 53: Base sequence of DNA fragment SEQ ID NOs: 54 to 57: primers SEQ ID NO: 58: Base sequence of DNA fragment SEQ ID NO: 59: Base sequence of DNA fragment-A SEQ ID NOs: 60 to 72: primers SEQ ID NO: 73: Base sequence of DNA fragment-P SEQ ID NO: 74: Base sequence of DNA fragment-Q SEQ ID NO: 75: Base sequence of DNA fragment SEQ ID NOs: 76 to 77: primers SEQ ID NO: 78: Nucleotide sequence of T7 promoter SEQ ID NOs: 79 to 90: primers

Claims

[Claim 1] A method for producing a target RNA, comprising the steps of: Cultivating a coryneform bacterium having an expression unit for a target RNA in a medium, expressing the target RNA, and accumulating the target RNA in the cells of the bacterium; collecting target RNA from the bacterial cells; Including, The bacterium is modified so that RNase III activity is reduced compared to a non-modified strain. The way it is done.

Citation Information

Patent Citations

  • Compositions and methods for improved RNA production and delivery by efficient transcription termination

    JP2016517274A

  • Double-stranded rna structures and constructs, and methods for generating and using the same

    US20060035344A1

  • RNA production method and promoter

    WO2009063969A1

  • Novel circular interfering RNA molecules

    WO2010084371A1